Christianson Syndrome

MONDO:0010278 Pathograph 26 Show in embeddings browser X-linked syndromic intellectual disability

An X-linked disorder caused by loss of function of SLC9A6, which encodes NHE6, the sodium-hydrogen exchanger of early and recycling endosomes. NHE6 supplies the proton leak that keeps endosomal pH from falling too far, so its loss over-acidifies the endosome and derails endosomal maturation, trafficking and the lysosomal system downstream of it. The clinical picture is unusual in being both neurodevelopmental and neurodegenerative in the same patient: impaired neuronal arborisation and synaptogenesis produce postnatal microcephaly, non-verbal status and severe intellectual disability, while progressive Purkinje cell loss and glycolipid storage produce a worsening ataxia and, in many, frank regression from the second decade. Affected males meet a tight set of core criteria; heterozygous females range from asymptomatic to mildly affected, in proportion to X-inactivation.

Ask OpenScientist

Ask a research question about Christianson Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
22
Phenotypes
26
Pathograph
1
Genes
3
Medical Actions
3
Models
12
References
1
Deep Research
👪

Inheritance

1
X-linked recessive HP:0001419
X-linked. Affected males are hemizygous. Heterozygous females range from asymptomatic to mildly affected with intellectual disability or behavioural difficulty, and the mouse work indicates the variability tracks mosaic expression of the mutant allele under X-inactivation.
X-linked recessive inheritance
Show evidence (4 references)
PMID:29334451 SUPPORT Human Clinical
"Manifestations in heterozygous females range from asymptomatic to mild ID and/or behavioral issues."
States the range of expression in heterozygous females.
PMID:29334451 SUPPORT Human Clinical
"Heterozygous (carrier) females have a 50% chance of transmitting the SLC9A6 pathogenic variant in each pregnancy."
The recurrence risk that follows from X-linked inheritance, quantified. This is the operative number in counselling, from the GeneReviews GENETIC COUNSELING section.
PMID:29334451 SUPPORT Human Clinical
"Sons who inherit the pathogenic variant will have CS; daughters who inherit the pathogenic variant may be asymptomatic or have mild ID and/or behavioral issues."
Splits the 50 percent transmission risk by sex of the offspring, which is what makes the figure actionable rather than abstract.
+ 1 more reference
⚙

Pathophysiology

6
SLC9A6 Loss of Function
The initiating lesion. A hemizygous loss-of-function variant in SLC9A6 eliminates NHE6 from early and recycling endosomes. Thirty-one distinct mutations are documented in the largest cohort, five of them recurrent across families, and 45 percent of cases with known inheritance arose de novo.
SLC9A6 hgnc:11079 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SLC9A6 (hgnc:11079). hgnc:11079 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Endosomal Over-Acidification NHE6 exchanges luminal protons for cations, supplying the leak that limits endosomal acidification. Without it the compartment over-acidifies.
Show evidence (2 references)
PMID:29334451 SUPPORT Human Clinical
"The diagnosis of CS is established in a male proband by identification of a hemizygous pathogenic variant in SLC9A6 on the X chromosome and in a female proband by identification of a heterozygous SLC9A6 pathogenic variant on molecular genetic testing."
States the causal gene and the zygosity requirement in each sex.
PMID:39237363 SUPPORT Human Clinical
"Of those with known inheritance (29 of 37 families), 16 cases were inherited (55%) and 13 cases were de novo (45%). Notably, 5 mutations were recurrent (ie, occurred in more than 1 family)."
Gives the de novo fraction and the number of recurrent alleles in the largest cohort.
Endosomal Over-Acidification
Endosomal pH falls below its set point. The direction matters and is easy to get backwards: NHE6 removes protons from the lumen, so losing it acidifies rather than alkalinises. A rare gain-of-function variant produces the opposite derangement, and causes disease too, which indicates the compartment is tuned rather than simply requiring acidity.
regulation of intracellular pH GO:0051453 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of intracellular pH (GO:0051453). GO:0051453 is a biological process from the Gene Ontology. ⚠ ABNORMAL
sodium:proton antiporter activity GO:0015385 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased sodium:proton antiporter activity (GO:0015385). GO:0015385 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Impaired Endosomal Maturation and Lysosomal Function Mis-set luminal pH disrupts the maturation and trafficking steps that depend on it, and the lysosomal system downstream inherits the defect.
Show evidence (1 reference)
PMID:30296617 SUPPORT In Vitro
"Compared to wild-type, G218R-containing endosomes were atypically alkaline and showed impaired uptake of recycling endosomal cargo."
The mirror-image experiment. A gain-of-function allele alkalinises the endosome and still impairs cargo uptake, which is why this node is framed as loss of pH control rather than as acidification alone.
Impaired Endosomal Maturation and Lysosomal Function
Endosome maturation and trafficking fail, and the lysosome is left deficient. In the mouse this looks like a lysosomal storage disorder in miniature and confined to particular neuronal populations: GM2 ganglioside and unesterified cholesterol accumulate, and beta-hexosaminidase activity becomes undetectable in exactly those neurons.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
endosomal transport GO:0016197 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased endosomal transport (GO:0016197). GO:0016197 is a biological process from the Gene Ontology. ↓ DECREASED lysosome organization GO:0007040 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal lysosome organization (GO:0007040). GO:0007040 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Animal models
Nhe6-null mouse Mouse recapitulates Reproduces the selective neuronal glycolipid and cholesterol storage with loss of beta-hexosaminidase activity, closely resembling a lysosomal storage disorder.
Heterozygous female Slc9a6 knockout mouse Mouse partially recapitulates Reproduces the storage and Purkinje cell pathology in mosaic distribution, matching the partial and variable phenotype of human female carriers.
Downstream
Reduced BDNF-TrkB Endosomal Signalling TrkB signals from endosomes and depends on Rab-mediated trafficking, which is disrupted here.
Progressive Neurodegeneration with Purkinje Cell Loss Storage and lysosomal failure precede the degenerative phase. The steps between them are not established, and the temporal ordering is the main evidence for the direction.
Show evidence (2 references)
PMID:21964919 SUPPORT Model Organism
"we found that sodium-hydrogen exchanger 6 depletion leads to abnormal accumulation of GM2 ganglioside and unesterified cholesterol within late endosomes and lysosomes of neurons in selective brain regions"
Documents the storage material and its selective regional distribution.
PMID:21964919 SUPPORT Model Organism
"In these select neuronal populations, histochemical staining for β-hexosaminidase activity, a lysosomal enzyme involved in the degradation of GM2 ganglioside, was undetectable."
Gives the enzymatic correlate of the storage, tying the accumulation to failed lysosomal degradation rather than to overproduction.
Reduced BDNF-TrkB Endosomal Signalling
Mechanism confidence: Provisional
TrkB and Akt phosphorylation fall. This is the arm that plausibly links a housekeeping trafficking defect to a specifically neuronal phenotype, since BDNF-TrkB signalling drives arborisation and synapse formation. It was demonstrated in the cochlea rather than in the forebrain, so its extension to the cognitive phenotype was, until recently, inference. A TrkB agonist rescue in hippocampal neurons has since supplied the forebrain evidence that was missing.
neurotrophin TRK receptor signaling pathway GO:0048011 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased neurotrophin TRK receptor signaling pathway (GO:0048011). GO:0048011 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Impaired Neuronal Arborisation and Synaptogenesis Reduced neurotrophin signalling is the proposed route to the arborisation and synaptogenesis defect, but the two were shown in different tissues and were not linked experimentally.
Show evidence (3 references)
PMID:32107410 SUPPORT Model Organism
"Nhe6 KO mice showed significant reductions in TrkB and Akt phosphorylation in the OC."
Direct measurement of reduced TrkB and Akt phosphorylation, in the organ of Corti.
PMID:39341363 SUPPORT Model Organism
"Significantly, the selective TrkB agonist 7,8-dihydroxyflavone restored spine density as well as functional and structural LTP in KO neurons."
A rescue experiment, and much stronger than correlation. Restoring TrkB signalling restores spine density and long-term potentiation in the hippocampus, which is the forebrain evidence the organ-of-Corti study could not provide.
PMID:39341363 SUPPORT Model Organism
"We uncovered significant reductions in dendritic spines density, AMPA receptor (AMPAR) expression, and AMPAR-mediated neurotransmission in CA1 pyramidal neurons."
Locates the synaptic deficit in hippocampal CA1 neurons, connecting this node to the arborisation and synaptogenesis node downstream.
Impaired Neuronal Arborisation and Synaptogenesis
The neurodevelopmental arm. Defective dendritic arborisation and synapse formation limit brain growth after birth, which is why the microcephaly is postnatal rather than congenital.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Postnatal Microcephaly Failure of postnatal brain growth produces a head circumference that falls away from the centiles after birth.
Severe Intellectual Disability The cognitive phenotype is attributed to the same developmental defect, though no experiment connects the two directly.
Absent Speech Non-verbal status is part of the same developmental outcome, and is among the most consistent features of the syndrome.
Autistic Behavior Autistic features and hyperactivity emerge from the same abnormal circuit development.
Hyperkinetic Movements Hyperkinesia belongs to the same developmental picture and, unlike the degenerative features, becomes less prominent with age.
Seizure Epilepsy arises on the abnormally developed cortex, beginning before age three. The specific circuit basis is not established in these sources.
Pain Insensitivity NHE6 is expressed in nociceptors, and its loss reduces cell-surface TRPV1, blunting responses to noxious thermal, mechanical and chemical stimuli. This is a separate route from the cognitive arm and reaches the sensory neuron directly.
Oropharyngeal Dysphagia Hypotonia and bulbar dysfunction in infancy impair swallowing.
Failure to Thrive Growth failure follows from the infantile hypotonia and dysphagia rather than from a primary growth defect, so both intermediates are named and curated separately.
Hypotonia Infantile hypotonia precedes the degenerative phase and tracks with the developmental rather than the neurodegenerative arm of the disease.
Eye Movement Abnormality Abnormal eye movements are among the defining neurologic findings. No cached source localises them to a specific circuit, so the intermediates are left unstated rather than assigned to the cerebellar arm on plausibility.
Show evidence (1 reference)
PMID:29349289 SUPPORT Model Organism
"Neuronal development is impaired in CS, involving defects in neuronal arborization and synaptogenesis, likely underlying diminished brain growth postnatally."
Names the cellular defect and its consequence for brain growth.
Progressive Neurodegeneration with Purkinje Cell Loss
The degenerative arm, and what makes this disorder unusual. Purkinje cells are lost early and rapidly, with a more protracted cerebral course behind it. In the rat this proceeds to amyloid-beta and tau aggregation, matching the tau deposition reported in human post-mortem material. Cerebellar atrophy is documented in 30 to 60% of patients.
Purkinje cell CL:0000121 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Purkinje cell (CL:0000121). CL:0000121 is a cell type from the Cell Ontology.
Animal models
Nhe6-null mouse Mouse recapitulates Reproduces progressive Purkinje cell loss beginning in the cerebellum, with wider cortical, hippocampal and striatal volume loss appearing later.
NHE6-null rat Rat recapitulates Reproduces early rapid Purkinje cell loss with a more protracted cerebral course, and establishes that the lysosomal defect precedes the neurodegeneration rather than following it.
Downstream
Ataxia Purkinje cell loss produces the progressive truncal ataxia that dominates the motor phenotype.
Cerebellar Atrophy Purkinje cell loss is visible on imaging as cerebellar atrophy, reported in 30 to 60% of patients.
Developmental Regression Continuing tissue loss produces loss of previously acquired skills, including ambulation and independent feeding.
Upper Motor Neuron Dysfunction The degenerative process is not confined to the cerebellum. Corticospinal tract signs appear in the majority over age ten, which is what makes the motor picture mixed rather than purely cerebellar.
Show evidence (2 references)
PMID:34928329 SUPPORT Model Organism
"NHE6-null rats demonstrated an early and rapid loss of Purkinje cells in the cerebellum, as well as a more protracted neurodegenerative course in the cerebrum."
Gives the two-speed course, cerebellar first and cerebral later.
PMID:29349289 SUPPORT Model Organism
"We report PC loss in two distinct Nhe6-null mouse models."
Independent replication of Purkinje cell loss across two separate mouse models, which is why this node is not treated as a single-model finding.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Christianson Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

22
Digestive 3
Oropharyngeal Dysphagia Oral-pharyngeal dysphagia HP:0200136 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Oral-pharyngeal dysphagia (HP:0200136). HP:0200136 is a phenotype from the Human Phenotype Ontology.
Sequelae: Failure to Thrive
Show evidence (1 reference)
PMID:29334451 SUPPORT Human Clinical
"Hypotonia and oropharyngeal dysphagia in infancy may result in failure to thrive."
Names the dysphagia and its nutritional consequence.
Gastroesophageal Reflux FREQUENT HP:0002020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gastroesophageal reflux (HP:0002020). HP:0002020 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2)."
Gives current GERD at 56 percent, which is the FREQUENT band.
Constipation FREQUENT HP:0002019 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Constipation (HP:0002019). HP:0002019 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2)."
Gives constipation at 55 percent, which is the FREQUENT band.
Eye 2
Eye Movement Abnormality FREQUENT Abnormality of eye movement HP:0000496 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of eye movement (HP:0000496). HP:0000496 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29334451 SUPPORT Human Clinical
"CLINICAL CHARACTERISTICS: Christianson syndrome (referred to as CS in this GeneReview), an X-linked disorder, is characterized in males by cognitive dysfunction, behavioral disorder, and neurologic findings (e.g., seizures, ataxia, postnatal microcephaly, and eye movement abnormalities)."
Names eye movement abnormality among the four neurologic findings that characterise the disorder.
PMID:39237363 SUPPORT Human Clinical
"Also noted is the unilateral inward deviation of the eye with eye movement abnormalities consistent with Duane anomaly; this was found in 68% of the current group"
68 percent of the cohort places this in the FREQUENT band.
Reduced Visual Acuity FREQUENT HP:0007663 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual acuity problems, annotated with Reduced visual acuity (HP:0007663). HP:0007663 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2)."
Gives visual acuity problems at 52 percent, which is the FREQUENT band.
Head and Neck 1
Postnatal Microcephaly VERY_FREQUENT Secondary microcephaly HP:0005484 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Secondary microcephaly (HP:0005484), qualified as course progressive. HP:0005484 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:39237363 SUPPORT Human Clinical
"Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%)."
Gives microcephaly at 95 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.
PMID:39237363 SUPPORT Human Clinical
"we show here that there is some evolution of these symptoms with age such that microcephaly, ataxia and high pain threshold have lower expression until after age 6. Notably, this provides further support that the microcephaly in CS is indeed postnatal microcephaly."
Establishes the postnatal and age-dependent emergence of this feature, which is why it is not a congenital finding; in the cohort table microcephaly is present in 80 percent of toddlers and all older participants.
Musculoskeletal 3
Hypotonia HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29334451 SUPPORT Human Clinical
"Hypotonia and oropharyngeal dysphagia in infancy may result in failure to thrive."
Names hypotonia in infancy and states its consequence, which is why it sits upstream of the failure to thrive already curated here.
Scoliosis FREQUENT HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Scoliosis occurred in 39% of participants; two participants had corrective surgeries for scoliosis between 15 and 20 years of age."
Gives scoliosis at 39 percent, which is the FREQUENT band, and its surgical management in adolescence.
Contractures FREQUENT Joint contracture HP:0034392 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Contractures, annotated with Joint contracture (HP:0034392). HP:0034392 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2)."
Gives contractures at 36 percent, which is the FREQUENT band.
Nervous System 12
Severe Intellectual Disability VERY_FREQUENT HP:0010864 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Severe intellectual disability (HP:0010864). HP:0010864 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:39237363 SUPPORT Human Clinical
"Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%)."
Gives intellectual disability at 100 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.
PMID:29334451 SUPPORT Human Clinical
"Males with CS typically present with developmental delay, later meeting criteria for severe intellectual disability (ID)."
States the developmental course into severe intellectual disability.
Absent Speech VERY_FREQUENT HP:0001344 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent speech (HP:0001344). HP:0001344 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%)."
Gives non-verbal status at 100 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.
Seizure VERY_FREQUENT HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:39237363 SUPPORT Human Clinical
"Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%)."
Gives epilepsy at 100 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.
PMID:29334451 SUPPORT Human Clinical
"Seizures, typically beginning before age three years, can include infantile spasms and tonic, tonic-clonic, myoclonic, and atonic seizures."
Gives the age at onset and the seizure semiology.
Ataxia VERY_FREQUENT HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251), qualified as course progressive. HP:0001251 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:39237363 SUPPORT Human Clinical
"Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%)."
Gives ataxia at 95 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.
PMID:39237363 SUPPORT BACKGROUND Human Clinical
"cerebellar degeneration in patients (atrophy in 30–60% of cases)"
Supports the cerebellar basis of the ataxia. It does not carry the frequency band, because it is the rate of cerebellar atrophy on imaging, banded on the Cerebellar Atrophy phenotype; the 30 to 60 percent figure is the paper's citation of earlier imaging series, not a measurement in its own cohort, hence BACKGROUND.
Hyperkinetic Movements VERY_FREQUENT HP:0002487 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperkinetic movements (HP:0002487). HP:0002487 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:39237363 SUPPORT Human Clinical
"Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%)."
Gives hyperkinesia at 93 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.
PMID:39237363 SUPPORT Human Clinical
"Furthermore, hyperkinesia appears to dissipate with age."
Records the decline in hyperkinesia with age.
Pain Insensitivity VERY_FREQUENT HP:0007021 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pain insensitivity (HP:0007021). HP:0007021 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"High pain tolerance, not previously identified as a core feature of CS, was present in 91% of probands."
91 percent places this in the VERY_FREQUENT band.
Developmental Regression FREQUENT HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Developmental regression (HP:0002376), qualified as course progressive. HP:0002376 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:39237363 SUPPORT Human Clinical
"The majority of probands (54%) had a history of parent-reported developmental regression that increased in prevalence across development with 30% of toddlers, 44% of children, 50% of adolescents, and 90% of adults experiencing prior regression."
54 percent overall places this in the FREQUENT band; the age gradient, from 30 percent of toddlers to 90 percent of adults, is what marks it as progressive.
PMID:39237363 SUPPORT Human Clinical
"Adaptive functioning was longitudinally examined; a majority of adult participants (18+ years) lost gross and fine motor skills over a 1 year follow-up."
Quantifies the rate of loss in adults over a defined interval, which is stronger than a retrospective history.
Autistic Behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29334451 SUPPORT Human Clinical
"Behaviorally, autism spectrum disorder and hyperactivity are common, and may resemble the behaviors observed in Angelman syndrome."
States the behavioural phenotype and its resemblance to Angelman syndrome.
Cerebellar Atrophy FREQUENT HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar atrophy (HP:0001272), qualified as course progressive. HP:0001272 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:39237363 SUPPORT BACKGROUND Human Clinical
"cerebellar degeneration in patients (atrophy in 30–60% of cases)"
Gives the atrophy rate, supporting both the phenotype and the FREQUENT band. The whole 30 to 60 percent range falls inside the FREQUENT band (30 to 79 percent), with its lower end on the boundary; the 30 to 60 percent figure is the paper's citation of earlier imaging series, not a measurement in its own cohort, hence BACKGROUND.
Upper Motor Neuron Dysfunction FREQUENT HP:0002493 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Upper motor neuron dysfunction (HP:0002493). HP:0002493 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"While neurologic examinations were consistent with cerebellar dysfunction, importantly, a majority of individuals (>50% older than 10) also had corticospinal tract abnormalities."
Gives both the proportion and the age dependence, and explicitly contrasts the corticospinal findings with the cerebellar ones.
Unprovoked Laughter FREQUENT Inappropriate laughter HP:0000748 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Unprovoked laughter, annotated with Inappropriate laughter (HP:0000748). HP:0000748 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2)."
Gives unprovoked laughter at 62 percent, which is the FREQUENT band.
Sleep Disturbance FREQUENT HP:0002360 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sleep disturbance (HP:0002360). HP:0002360 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2)."
Gives current sleep problems at 51 percent, which is the FREQUENT band.
Growth 1
Failure to Thrive HP:0001508 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Failure to thrive (HP:0001508). HP:0001508 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"The rate of growth across development was slow and resulted in prominently decreased age-normed height and weight by adulthood."
Extends the infantile feeding problem into a lifelong growth deficit measured relative to age norms.
🧬

Genetic Associations

1
SLC9A6 (Loss of Function, X-linked)
Gene: SLC9A6 hgnc:11079 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SLC9A6 (hgnc:11079). hgnc:11079 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:29334451 SUPPORT Human Clinical
"The diagnosis of CS is established in a male proband by identification of a hemizygous pathogenic variant in SLC9A6 on the X chromosome and in a female proband by identification of a heterozygous SLC9A6 pathogenic variant on molecular genetic testing."
States the causal relationship and the molecular diagnostic criterion.
PMID:30296617 SUPPORT Human Clinical
"The patient manifested several core symptoms typical of CS, including pronounced cognitive impairment, mutism, epilepsy, ataxia and microcephaly; however, deterioration of motor function often observed after the first decade of life in CS children with total loss of SLC9A6/NHE6 function was not evident."
Documents the gain-of-function allele producing the core phenotype without the later motor deterioration, which is the basis for the allelic nuance in these notes.
💊

Medical Actions

3
Seizure Management
Action: pharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Platform: Small molecule
Anticonvulsant treatment per standard care. There is no disease-modifying therapy, and seizure control is among the treatment priorities caregivers name most often.
Show evidence (2 references)
PMID:29334451 SUPPORT Human Clinical
"Treatment of manifestations: Management of neurodevelopmental disorders, feeding difficulties, and seizures are per standard care."
States that management is symptomatic and follows standard care rather than any disease-specific protocol.
PMID:40170533 SUPPORT Human Clinical
"Caregivers emphasized connecting with other families and prioritized treatments for seizures, communication, and preventing regressions."
Records seizure control as a caregiver-stated treatment priority, which is the evidence that this target matters to patients rather than only to clinicians.
Supportive and Nutritional Care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Platform: Behavioral / lifestyle
Management of feeding difficulty and of the neurodevelopmental disorder, with surveillance of growth. Given the lifelong slow growth and the infantile dysphagia, nutrition is a recurring rather than a one-off problem.
Show evidence (1 reference)
PMID:29334451 SUPPORT Human Clinical
"Treatment of manifestations: Management of neurodevelopmental disorders, feeding difficulties, and seizures are per standard care."
Names feeding difficulty and neurodevelopmental management as the components of supportive care here.
Regression Surveillance
Action: clinical evaluation for skill lossNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is clinical evaluation for skill loss, annotated with Clinical Evaluation (NCIT:C124351). NCIT:C124351 is a clinical intervention from the NCI Thesaurus. Ontology label: Clinical Evaluation NCIT:C124351
Platform: Other
Structured surveillance for skill loss in adolescents and young adults. This is the management recommendation that follows directly from the biphasic course this entry models: the developmental phase is not the whole disease, and the point of surveillance is to detect the degenerative phase when it starts rather than in retrospect.
Mechanism Target:
MODULATES Developmental Regression — Surveillance does not prevent regression. It changes when regression is recognised, which is what makes supportive intervention possible at all.
Show evidence (1 reference)
PMID:29334451 SUPPORT Human Clinical
"Detailed history and related assessments in adolescents and young adults for evidence of possible loss of any of the following skills: feeding, fine/gross motor skills, ambulation, and use of words/sounds."
Names the specific skills to be tracked, which are the same domains in which the longitudinal study documents measured loss.
Show evidence (1 reference)
PMID:29334451 SUPPORT Human Clinical
"Surveillance: At the time of follow-up clinical examinations, the following are recommended: Measurement of weight and height (and calculation of body mass index)."
Establishes that GeneReviews specifies a surveillance schedule rather than leaving follow-up unstructured.
🔬

Diagnosis

1
SLC9A6 molecular genetic testing (PRESENT)
The diagnosis is molecular. Clinical recognition is unreliable on its own because the phenotype overlaps Angelman syndrome closely enough that Christianson syndrome appears in the differential of Angelman-negative patients.
Show evidence (2 references)
PMID:29334451 SUPPORT Human Clinical
"The diagnosis of CS is established in a male proband by identification of a hemizygous pathogenic variant in SLC9A6 on the X chromosome and in a female proband by identification of a heterozygous SLC9A6 pathogenic variant on molecular genetic testing."
States the molecular diagnostic criterion for each sex.
PMID:24779060 SUPPORT Human Clinical
"Angelman syndrome (AS) is caused by a lack of expression of the maternally inherited UBE3A gene in the brain. However, about 10% of individuals with a clinical diagnosis of AS do not have an identifiable molecular defect."
Establishes the Angelman-negative population in which this diagnosis is considered, which is the practical route to recognising it.
🌍

Epidemiology

2
Core diagnostic criteria
Six core features are present in over 85% of affected males, and universally present between ages 6 and 16: non-verbal status, intellectual disability, epilepsy, postnatal microcephaly, ataxia and hyperkinesia. High pain tolerance was added as a seventh core feature at 91%.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"Previously defined core diagnostic criteria for CS (present in>85%)-namely non-verbal status, intellectual disability, epilepsy, postnatal microcephaly, ataxia, hyperkinesia-were universally present in age 6-16; however, an additional core feature of high pain tolerance was added (present in 91%)."
Enumerates the core criteria with their frequencies and the age window in which they are fully penetrant.
Cohort size and allelic diversity
The largest prospective series followed 44 individuals carrying 31 distinct NHE6 mutations from age 2 to 32, which is the basis for most of what is known about the adult phenotype.
Show evidence (1 reference)
PMID:39237363 SUPPORT Human Clinical
"44 individuals with 31 unique NHE6 mutations, age 2-32 years, were followed prospectively, herein reporting baseline, 1 year follow-up and retrospective natural history."
Gives the cohort size and the allelic heterogeneity behind the natural history data used throughout this entry.
🐁

Animal Models

3
Nhe6-null mouse
The principal model, and unusual in reproducing both halves of the human disease. Brain volume changes reflect undergrowth and tissue loss together, with Purkinje cell loss confirmed in two independent knockout lines.
Species
Mouse
Genotype
Slc9a6 knockout
Publication
PMID:29349289
Pathograph links
Progressive Neurodegeneration with Purkinje Cell Loss recapitulates fidelity: high Reproduces progressive Purkinje cell loss beginning in the cerebellum, with wider cortical, hippocampal and striatal volume loss appearing later.
Limitations: Mice do not accumulate insoluble endogenous tau or amyloid-beta, so this model cannot address the tau deposition reported in human post-mortem material. That is what the rat model below was made for.
Show evidence (1 reference)
PMID:29349289 SUPPORT Model Organism
"Reductions in volume are first apparent at 2 mo, particularly in the cerebellum, which demonstrates progressive loss of Purkinje cells (PCs)."
Gives the timing and regional onset of the degeneration this link records.
Impaired Endosomal Maturation and Lysosomal Function recapitulates fidelity: high Reproduces the selective neuronal glycolipid and cholesterol storage with loss of beta-hexosaminidase activity, closely resembling a lysosomal storage disorder.
Limitations: The storage is regionally selective rather than global, so the model does not explain why particular neuronal populations are vulnerable.
Show evidence (1 reference)
PMID:21964919 SUPPORT Model Organism
"we found that sodium-hydrogen exchanger 6 depletion leads to abnormal accumulation of GM2 ganglioside and unesterified cholesterol within late endosomes and lysosomes of neurons in selective brain regions"
Documents the storage phenotype that this link records.
Show evidence (1 reference)
PMID:29349289 SUPPORT Model Organism
"We report PC loss in two distinct Nhe6-null mouse models."
Replication across two independent lines, which is why the finding is not treated as model-specific.
NHE6-null rat
Built specifically because mice do not deposit endogenous tau or amyloid-beta. The choice of species is itself the experimental design, which is worth noting because it means the tau result could not have been obtained in the mouse.
Species
Rat
Genotype
NHE6 null, CRISPR-Cas9
Publication
PMID:34928329
Pathograph links
Progressive Neurodegeneration with Purkinje Cell Loss recapitulates fidelity: high Reproduces early rapid Purkinje cell loss with a more protracted cerebral course, and establishes that the lysosomal defect precedes the neurodegeneration rather than following it.
Limitations: Ordering in a rodent lifespan does not establish the same ordering in a human course measured in decades.
Show evidence (1 reference)
PMID:34928329 SUPPORT Model Organism
"NHE6-null rats demonstrated an early and rapid loss of Purkinje cells in the cerebellum, as well as a more protracted neurodegenerative course in the cerebrum."
Gives the two-speed degeneration this link records.
Show evidence (1 reference)
PMID:34928329 SUPPORT Model Organism
"Mouse models generally do not show the accumulation of insoluble, endogenously-expressed (non-transgenic) tau or amyloid-β."
States the limitation of the mouse that motivated building this model.
Heterozygous female Slc9a6 knockout mouse
Addresses the female carrier question directly by using a lacZ reporter knocked into the mutant allele, so X-inactivation can be visualised alongside the pathology it produces.
Species
Mouse
Genotype
Slc9a6 KO heterozygous female, lacZ reporter
Publication
PMID:26515654
Pathograph links
Impaired Endosomal Maturation and Lysosomal Function partially recapitulates fidelity: moderate Reproduces the storage and Purkinje cell pathology in mosaic distribution, matching the partial and variable phenotype of human female carriers.
Limitations: Mouse X-inactivation patterns need not match human ones, so the model supports the mechanism of variability rather than predicting any individual carrier's severity.
Show evidence (1 reference)
PMID:26515654 SUPPORT Model Organism
"we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous Slc9a6 KO female mice"
Documents the mosaic pathology this link records.
Show evidence (1 reference)
PMID:26515654 SUPPORT Model Organism
"In heterozygous female Slc9a6 KO mice, β-Gal serves as a transcriptional/XCI reporter and thus facilitates testing of effects of mosaic expression of the mutant allele on penetrance of the abnormal phenotype."
Describes the reporter design that makes mosaic expression directly observable.
{ }

Source YAML

click to show 
name: Christianson Syndrome
creation_date: '2026-09-04T17:00:00Z'
description: >-
  An X-linked disorder caused by loss of function of SLC9A6, which encodes NHE6,
  the sodium-hydrogen exchanger of early and recycling endosomes. NHE6 supplies
  the proton leak that keeps endosomal pH from falling too far, so its loss
  over-acidifies the endosome and derails endosomal maturation, trafficking and
  the lysosomal system downstream of it. The clinical picture is unusual in being
  both neurodevelopmental and neurodegenerative in the same patient: impaired
  neuronal arborisation and synaptogenesis produce postnatal microcephaly,
  non-verbal status and severe intellectual disability, while progressive
  Purkinje cell loss and glycolipid storage produce a worsening ataxia and, in
  many, frank regression from the second decade. Affected males meet a tight set
  of core criteria; heterozygous females range from asymptomatic to mildly
  affected, in proportion to X-inactivation.
categories:
- X-linked Intellectual Disability
- Endosomal Trafficking Disorder
- Neurodevelopmental and Neurodegenerative Disorder
parents:
- X-linked syndromic intellectual disability
synonyms:
- X-linked Angelman-like syndrome
- MRXSCH
- intellectual disability, X-linked syndromic, Christianson type
epidemiology:
- name: Core diagnostic criteria
  description: >-
    Six core features are present in over 85% of affected males, and universally
    present between ages 6 and 16: non-verbal status, intellectual disability,
    epilepsy, postnatal microcephaly, ataxia and hyperkinesia. High pain
    tolerance was added as a seventh core feature at 91%.
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Previously defined core diagnostic criteria for CS (present in>85%)-namely non-verbal status, intellectual disability, epilepsy, postnatal microcephaly, ataxia, hyperkinesia-were universally present in age 6-16; however, an additional core feature of high pain tolerance was added (present in 91%).'
    explanation: 'Enumerates the core criteria with their frequencies and the age window in which they are fully penetrant.'
- name: Cohort size and allelic diversity
  description: >-
    The largest prospective series followed 44 individuals carrying 31 distinct
    NHE6 mutations from age 2 to 32, which is the basis for most of what is known
    about the adult phenotype.
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: '44 individuals with 31 unique NHE6 mutations, age 2-32 years, were followed prospectively, herein reporting baseline, 1 year follow-up and retrospective natural history.'
    explanation: 'Gives the cohort size and the allelic heterogeneity behind the natural history data used throughout this entry.'
pathophysiology:
- name: SLC9A6 Loss of Function
  biological_scale: MOLECULAR
  description: >-
    The initiating lesion. A hemizygous loss-of-function variant in SLC9A6
    eliminates NHE6 from early and recycling endosomes. Thirty-one distinct
    mutations are documented in the largest cohort, five of them recurrent across
    families, and 45 percent of cases with known inheritance arose de novo.
  genes:
  - preferred_term: SLC9A6
    term:
      id: hgnc:11079
      label: SLC9A6
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The diagnosis of CS is established in a male proband by identification of a hemizygous
      pathogenic variant in SLC9A6 on the X chromosome and in a female proband by identification
      of a heterozygous SLC9A6 pathogenic variant on molecular genetic testing.'
    explanation: States the causal gene and the zygosity requirement in each sex.
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Of those with known inheritance (29 of 37 families), 16 cases were inherited (55%) and 13 cases were de novo (45%). Notably, 5 mutations were recurrent (ie, occurred in more than 1 family).'
    explanation: 'Gives the de novo fraction and the number of recurrent alleles in the largest cohort.'
  downstream:
  - target: Endosomal Over-Acidification
    causal_link_type: DIRECT
    description: NHE6 exchanges luminal protons for cations, supplying the leak that limits
      endosomal acidification. Without it the compartment over-acidifies.
    evidence:
    - reference: PMID:30296617
      reference_title: A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and
        neuronal atrophy associated with Christianson Syndrome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: 'Loss-of-function mutations in the recycling endosomal (Na+,K+)/H+ exchanger gene
        SLC9A6/NHE6 result in overacidification and dysfunction of endosomal-lysosomal
        compartments, and cause a neurodevelopmental and degenerative form of X-linked
        intellectual disability called Christianson Syndrome (CS).'
      explanation: States the direction of the pH change and names it as the cause of the
        endosomal-lysosomal dysfunction downstream.
- name: Endosomal Over-Acidification
  biological_scale: MOLECULAR
  description: >-
    Endosomal pH falls below its set point. The direction matters and is easy to
    get backwards: NHE6 removes protons from the lumen, so losing it acidifies
    rather than alkalinises. A rare gain-of-function variant produces the opposite
    derangement, and causes disease too, which indicates the compartment is tuned
    rather than simply requiring acidity.
  biological_processes:
  - preferred_term: regulation of intracellular pH
    modifier: ABNORMAL
    term:
      id: GO:0051453
      label: regulation of intracellular pH
  molecular_functions:
  - preferred_term: sodium:proton antiporter activity
    modifier: DECREASED
    term:
      id: GO:0015385
      label: sodium:proton antiporter activity
  evidence:
  - reference: PMID:30296617
    reference_title: A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and
      neuronal atrophy associated with Christianson Syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: 'Compared to wild-type, G218R-containing endosomes were atypically alkaline and showed
      impaired uptake of recycling endosomal cargo.'
    explanation: The mirror-image experiment. A gain-of-function allele alkalinises the endosome
      and still impairs cargo uptake, which is why this node is framed as loss of pH control
      rather than as acidification alone.
  downstream:
  - target: Impaired Endosomal Maturation and Lysosomal Function
    causal_link_type: DIRECT
    description: Mis-set luminal pH disrupts the maturation and trafficking steps that depend on
      it, and the lysosomal system downstream inherits the defect.
    evidence:
    - reference: PMID:34928329
      reference_title: Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in
        NHE6-null rat brain.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'We have recently shown that loss of NHE6 causes defects in endosome maturation
        and trafficking underlying lysosome deficiency in primary mouse neurons in vitro.'
      explanation: States the maturation and trafficking defect and its lysosomal consequence,
        which is what this edge asserts.
- name: Impaired Endosomal Maturation and Lysosomal Function
  biological_scale: CELLULAR
  description: >-
    Endosome maturation and trafficking fail, and the lysosome is left deficient.
    In the mouse this looks like a lysosomal storage disorder in miniature and
    confined to particular neuronal populations: GM2 ganglioside and unesterified
    cholesterol accumulate, and beta-hexosaminidase activity becomes undetectable
    in exactly those neurons.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: endosomal transport
    modifier: DECREASED
    term:
      id: GO:0016197
      label: endosomal transport
  - preferred_term: lysosome organization
    modifier: ABNORMAL
    term:
      id: GO:0007040
      label: lysosome organization
  evidence:
  - reference: PMID:21964919
    reference_title: X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of
      endosomal-lysosomal dysfunction.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'we found that sodium-hydrogen exchanger 6 depletion leads to abnormal accumulation
      of GM2 ganglioside and unesterified cholesterol within late endosomes and lysosomes of
      neurons in selective brain regions'
    explanation: Documents the storage material and its selective regional distribution.
  - reference: PMID:21964919
    reference_title: X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of
      endosomal-lysosomal dysfunction.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'In these select neuronal populations, histochemical staining for β-hexosaminidase
      activity, a lysosomal enzyme involved in the degradation of GM2 ganglioside, was
      undetectable.'
    explanation: Gives the enzymatic correlate of the storage, tying the accumulation to failed
      lysosomal degradation rather than to overproduction.
  downstream:
  - target: Reduced BDNF-TrkB Endosomal Signalling
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: TrkB signals from endosomes and depends on Rab-mediated trafficking, which is
      disrupted here.
    evidence:
    - reference: PMID:32107410
      reference_title: 'Sodium-hydrogen exchanger 6 (NHE6) deficiency leads to hearing loss, via reduced endosomal
        signalling through the BDNF/Trk pathway.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'We found no change in Rab5, significantly lower Rab7, and higher Rab11 levels in
        the Nhe6 KO OC, compared to WT littermates. Because Rabs mediate TrkB endosomal
        signalling, we evaluated TrkB phosphorylation in the OCs of both strains.'
      explanation: Names the Rab intermediates that connect the trafficking defect to TrkB
        signalling, which is why this edge is graded as having known intermediates.
  - target: Progressive Neurodegeneration with Purkinje Cell Loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Storage and lysosomal failure precede the degenerative phase. The steps between
      them are not established, and the temporal ordering is the main evidence for the direction.
    evidence:
    - reference: PMID:34928329
      reference_title: Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in
        NHE6-null rat brain.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'NHE6-null rats demonstrated an early and rapid loss of Purkinje cells in the
        cerebellum, as well as a more protracted neurodegenerative course in the cerebrum.'
      explanation: Establishes the ordering, with lysosomal defects preceding the
        neurodegeneration this edge terminates in.
- name: Reduced BDNF-TrkB Endosomal Signalling
  biological_scale: CELLULAR
  description: >-
    TrkB and Akt phosphorylation fall. This is the arm that plausibly links a
    housekeeping trafficking defect to a specifically neuronal phenotype, since
    BDNF-TrkB signalling drives arborisation and synapse formation. It was
    demonstrated in the cochlea rather than in the forebrain, so its extension to
    the cognitive phenotype was, until recently, inference. A TrkB agonist rescue in
    hippocampal neurons has since supplied the forebrain evidence that was missing.
  biological_processes:
  - preferred_term: neurotrophin TRK receptor signaling pathway
    modifier: DECREASED
    term:
      id: GO:0048011
      label: neurotrophin TRK receptor signaling pathway
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:32107410
    reference_title: 'Sodium-hydrogen exchanger 6 (NHE6) deficiency leads to hearing loss, via reduced endosomal
      signalling through the BDNF/Trk pathway.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'Nhe6 KO mice showed significant reductions in TrkB and Akt phosphorylation in the
      OC.'
    explanation: Direct measurement of reduced TrkB and Akt phosphorylation, in the organ of
      Corti.
  - reference: PMID:39341363
    reference_title: Impaired hippocampal plasticity associated with loss of recycling endosomal SLC9A6/NHE6
      is ameliorated by the TrkB agonist 7,8-dihydroxyflavone.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'Significantly, the selective TrkB agonist 7,8-dihydroxyflavone restored spine density
      as well as functional and structural LTP in KO neurons.'
    explanation: A rescue experiment, and much stronger than correlation. Restoring TrkB signalling
      restores spine density and long-term potentiation in the hippocampus, which is the forebrain
      evidence the organ-of-Corti study could not provide.
  - reference: PMID:39341363
    reference_title: Impaired hippocampal plasticity associated with loss of recycling endosomal SLC9A6/NHE6
      is ameliorated by the TrkB agonist 7,8-dihydroxyflavone.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'We uncovered significant reductions in dendritic spines density, AMPA receptor (AMPAR)
      expression, and AMPAR-mediated neurotransmission in CA1 pyramidal neurons.'
    explanation: Locates the synaptic deficit in hippocampal CA1 neurons, connecting this node to
      the arborisation and synaptogenesis node downstream.
  downstream:
  - target: Impaired Neuronal Arborisation and Synaptogenesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Reduced neurotrophin signalling is the proposed route to the arborisation and
      synaptogenesis defect, but the two were shown in different tissues and were not linked
      experimentally.
    evidence:
    - reference: PMID:29349289
      reference_title: Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of
        Christianson Syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'Neuronal development is impaired in CS, involving defects in neuronal arborization
        and synaptogenesis, likely underlying diminished brain growth postnatally.'
      explanation: States the arborisation and synaptogenesis defect and its proposed link to
        brain undergrowth, using the authors' own hedge.
- name: Impaired Neuronal Arborisation and Synaptogenesis
  biological_scale: CELLULAR
  description: >-
    The neurodevelopmental arm. Defective dendritic arborisation and synapse
    formation limit brain growth after birth, which is why the microcephaly is
    postnatal rather than congenital.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:29349289
    reference_title: Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of
      Christianson Syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'Neuronal development is impaired in CS, involving defects in neuronal arborization
      and synaptogenesis, likely underlying diminished brain growth postnatally.'
    explanation: Names the cellular defect and its consequence for brain growth.
  downstream:
  - target: Postnatal Microcephaly
    causal_link_type: DIRECT
    description: Failure of postnatal brain growth produces a head circumference that falls away
      from the centiles after birth.
    evidence:
    - reference: PMID:29349289
      reference_title: Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of
        Christianson Syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'We report trajectories of volume changes in the mutant that likely reflect both
        brain undergrowth as well as tissue loss.'
      explanation: Separates undergrowth from tissue loss as contributors to the volume deficit,
        which is the distinction this edge depends on.
  - target: Severe Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The cognitive phenotype is attributed to the same developmental defect, though
      no experiment connects the two directly.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Males with CS typically present with developmental delay, later meeting criteria
        for severe intellectual disability (ID).'
      explanation: Establishes the cognitive endpoint; the causal attribution to arborisation is
        inference, which is why the edge is graded as having unknown intermediates.
  - target: Absent Speech
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Non-verbal status is part of the same developmental outcome, and is among the
      most consistent features of the syndrome.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Males with CS typically present with developmental delay, later meeting criteria
        for severe intellectual disability (ID).'
      explanation: Places non-verbal status within the same developmental trajectory; no source
        here dissects speech from general cognitive outcome, hence the grading.
  - target: Autistic Behavior
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Autistic features and hyperactivity emerge from the same abnormal circuit
      development.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Behaviorally, autism spectrum disorder and hyperactivity are common, and may resemble
        the behaviors observed in Angelman syndrome.'
      explanation: Names the behavioural phenotype attributed to this arm.
  - target: Hyperkinetic Movements
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hyperkinesia belongs to the same developmental picture and, unlike the
      degenerative features, becomes less prominent with age.
    evidence:
    - reference: PMID:39237363
      reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Furthermore, hyperkinesia appears to dissipate with age.'
      explanation: 'The decline with age distinguishes this from the progressive degenerative features and is why it is placed on the developmental arm; in the cohort table hyperkinesia falls from 100 percent in children to 82 percent in adults.'
  - target: Seizure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Epilepsy arises on the abnormally developed cortex, beginning before age three.
      The specific circuit basis is not established in these sources.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Seizures, typically beginning before age three years, can include infantile spasms
        and tonic, tonic-clonic, myoclonic, and atonic seizures.'
      explanation: Gives the early onset consistent with a developmental rather than degenerative
        origin, while the mechanism itself is unestablished.
  - target: Pain Insensitivity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: NHE6 is expressed in nociceptors, and its loss reduces cell-surface TRPV1,
      blunting responses to noxious thermal, mechanical and chemical stimuli. This is a separate
      route from the cognitive arm and reaches the sensory neuron directly.
    evidence:
    - reference: PMID:39237363
      reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'High pain tolerance, not previously identified as a core feature of CS, was present in 91% of probands.'
      explanation: 'Establishes the human feature and its frequency.'
    - reference: PMID:32569089
      reference_title: Loss of SLC9A6/NHE6 impairs nociception in a mouse model of Christianson syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'Behaviourally, Nhe6 KO mice have decreased nocifensive responses to acute noxious
        thermal, mechanical, and chemical (ie, capsaicin) stimuli. The reduced capsaicin sensitivity
        in the KO mice correlates with a decreased expression of the transient receptor potential
        channel TRPV1 at the plasma membrane'
      explanation: Supplies the mechanism - reduced surface TRPV1 in nociceptors - that places this
        edge at INDIRECT_KNOWN_INTERMEDIATES.
  - target: Oropharyngeal Dysphagia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Hypotonia and bulbar dysfunction in infancy impair swallowing.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Hypotonia and oropharyngeal dysphagia in infancy may result in failure to thrive.'
      explanation: Names the dysphagia in the infantile period alongside the hypotonia it
        accompanies.
  - target: Failure to Thrive
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Growth failure follows from the infantile hypotonia and dysphagia rather than
      from a primary growth defect, so both intermediates are named and curated separately.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Hypotonia and oropharyngeal dysphagia in infancy may result in failure to
        thrive.'
      explanation: Names both intermediates and the outcome in one sentence, which is what makes
        this an INDIRECT_KNOWN_INTERMEDIATES link rather than an unknown one.
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Infantile hypotonia precedes the degenerative phase and tracks with the
      developmental rather than the neurodegenerative arm of the disease.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Hypotonia and oropharyngeal dysphagia in infancy may result in failure to
        thrive.'
      explanation: Places hypotonia in infancy, alongside the dysphagia already attached to this
        node.
  - target: Eye Movement Abnormality
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Abnormal eye movements are among the defining neurologic findings. No cached
      source localises them to a specific circuit, so the intermediates are left unstated rather
      than assigned to the cerebellar arm on plausibility.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'CLINICAL CHARACTERISTICS: Christianson syndrome (referred to as CS in this
        GeneReview), an X-linked disorder, is characterized in males by cognitive dysfunction,
        behavioral disorder, and neurologic findings (e.g., seizures, ataxia, postnatal
        microcephaly, and eye movement abnormalities).'
      explanation: Groups eye movement abnormality with the other neurologic findings without
        localising it.
- name: Progressive Neurodegeneration with Purkinje Cell Loss
  biological_scale: TISSUE
  description: >-
    The degenerative arm, and what makes this disorder unusual. Purkinje cells are
    lost early and rapidly, with a more protracted cerebral course behind it. In
    the rat this proceeds to amyloid-beta and tau aggregation, matching the tau
    deposition reported in human post-mortem material. Cerebellar atrophy is
    documented in 30 to 60% of patients.
  cell_types:
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  evidence:
  - reference: PMID:34928329
    reference_title: Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in
      NHE6-null rat brain.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'NHE6-null rats demonstrated an early and rapid loss of Purkinje cells in the
      cerebellum, as well as a more protracted neurodegenerative course in the cerebrum.'
    explanation: Gives the two-speed course, cerebellar first and cerebral later.
  - reference: PMID:29349289
    reference_title: Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of
      Christianson Syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'We report PC loss in two distinct Nhe6-null mouse models.'
    explanation: Independent replication of Purkinje cell loss across two separate mouse models,
      which is why this node is not treated as a single-model finding.
  downstream:
  - target: Ataxia
    causal_link_type: DIRECT
    description: Purkinje cell loss produces the progressive truncal ataxia that dominates the
      motor phenotype.
    evidence:
    - reference: PMID:39237363
      reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Subjects have evidence of cerebellar dysfunction including tremor and truncal ataxia as evidenced by wide-based gait.'
      explanation: 'Direct neurological examination finds truncal ataxia together with other cerebellar signs, which is the clinical counterpart of Purkinje cell loss.'
  - target: Cerebellar Atrophy
    causal_link_type: DIRECT
    description: Purkinje cell loss is visible on imaging as cerebellar atrophy, reported in 30
      to 60% of patients.
    evidence:
    - reference: PMID:39237363
      reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
      supports: SUPPORT
      quote_role: BACKGROUND
      evidence_source: HUMAN_CLINICAL
      snippet: 'cerebellar degeneration in patients (atrophy in 30–60% of cases)'
      explanation: 'Gives the imaging correlate and its frequency; the 30 to 60 percent figure is the paper''s citation of earlier imaging series, not a measurement in its own cohort, hence BACKGROUND.'
  - target: Developmental Regression
    causal_link_type: DIRECT
    description: Continuing tissue loss produces loss of previously acquired skills, including
      ambulation and independent feeding.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Subsequently, regression (e.g., loss of ambulation and ability to feed
        independently) may occur.'
      explanation: Names the specific skills lost, which is what distinguishes regression from
        static disability here.
  - target: Upper Motor Neuron Dysfunction
    causal_link_type: DIRECT
    description: The degenerative process is not confined to the cerebellum. Corticospinal tract
      signs appear in the majority over age ten, which is what makes the motor picture mixed
      rather than purely cerebellar.
    evidence:
    - reference: PMID:39237363
      reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Importantly, also older patients (ie, age 20 and greater) present with evidence of motor dysfunction with signs of corticospinal tract, i.e., upper motor neuron damage such as increased tone, weakness, increased and abnormal reflexes.'
      explanation: 'Direct examination finds corticospinal signs in older patients alongside the cerebellar ones, which is the basis for attaching this to the degenerative node.'
phenotypes:
- category: Neurologic
  name: Severe Intellectual Disability
  frequency: VERY_FREQUENT
  description: >-
    Present in essentially all affected males and one of the six core criteria.
    Presents first as developmental delay.
  phenotype_term:
    preferred_term: Severe intellectual disability
    term:
      id: HP:0010864
      label: Severe intellectual disability
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%).'
    explanation: 'Gives intellectual disability at 100 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.'
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Males with CS typically present with developmental delay, later meeting criteria
      for severe intellectual disability (ID).'
    explanation: States the developmental course into severe intellectual disability.
- category: Neurologic
  name: Absent Speech
  frequency: VERY_FREQUENT
  description: >-
    Non-verbal status is a core criterion and among the most consistent features.
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%).'
    explanation: 'Gives non-verbal status at 100 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.'
- category: Neurologic
  name: Seizure
  frequency: VERY_FREQUENT
  description: >-
    Epilepsy is a core criterion, typically beginning before age three, and
    includes infantile spasms and tonic, tonic-clonic, myoclonic and atonic
    seizure types.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%).'
    explanation: 'Gives epilepsy at 100 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.'
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Seizures, typically beginning before age three years, can include infantile spasms
      and tonic, tonic-clonic, myoclonic, and atonic seizures.'
    explanation: Gives the age at onset and the seizure semiology.
- category: Neurologic
  name: Postnatal Microcephaly
  frequency: VERY_FREQUENT
  description: >-
    Head circumference falls away after birth rather than being small at birth,
    which reflects failure of postnatal brain growth. Often not apparent before
    age six.
  phenotype_term:
    preferred_term: Secondary microcephaly
    term:
      id: HP:0005484
      label: Secondary microcephaly
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%).'
    explanation: 'Gives microcephaly at 95 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.'
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'we show here that there is some evolution of these symptoms with age such that microcephaly, ataxia and high pain threshold have lower expression until after age 6. Notably, this provides further support that the microcephaly in CS is indeed postnatal microcephaly.'
    explanation: 'Establishes the postnatal and age-dependent emergence of this feature, which is why it is not a congenital finding; in the cohort table microcephaly is present in 80 percent of toddlers and all older participants.'
- category: Neurologic
  name: Ataxia
  frequency: VERY_FREQUENT
  description: >-
    Progressive truncal ataxia, a core criterion, attributable to Purkinje cell
    loss. Cerebellar atrophy is reported in 30 to 60% of patients.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%).'
    explanation: 'Gives ataxia at 95 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.'
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: 'cerebellar degeneration in patients (atrophy in 30–60% of cases)'
    explanation: 'Supports the cerebellar basis of the ataxia. It does not carry the frequency band, because it is the rate of cerebellar atrophy on imaging, banded on the Cerebellar Atrophy phenotype; the 30 to 60 percent figure is the paper''s citation of earlier imaging series, not a measurement in its own cohort, hence BACKGROUND.'
- category: Neurologic
  name: Hyperkinetic Movements
  frequency: VERY_FREQUENT
  description: >-
    A core criterion in childhood, though it becomes less prominent after age
    sixteen, which is one of the clearer examples of the phenotype evolving with
    age.
  phenotype_term:
    preferred_term: Hyperkinetic movements
    term:
      id: HP:0002487
      label: Hyperkinetic movements
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Specifically, all of the core symptoms were present in greater than 85%, including ID (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%) and hyperkinesia (93%).'
    explanation: 'Gives hyperkinesia at 93 percent in the cohort of 44, which is the VERY_FREQUENT band. None of the six core features is banded OBLIGATE, because the study states universal presence only for ages 6 to 16.'
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Furthermore, hyperkinesia appears to dissipate with age.'
    explanation: 'Records the decline in hyperkinesia with age.'
- category: Neurologic
  name: Pain Insensitivity
  frequency: VERY_FREQUENT
  description: >-
    High pain tolerance, added as a seventh core feature at 91% in the
    longitudinal cohort. It is easily missed and has practical consequences,
    because injury and illness may not be signalled in a non-verbal patient.
  phenotype_term:
    preferred_term: Pain insensitivity
    term:
      id: HP:0007021
      label: Pain insensitivity
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'High pain tolerance, not previously identified as a core feature of CS, was present in 91% of probands.'
    explanation: '91 percent places this in the VERY_FREQUENT band.'
- category: Neurologic
  name: Developmental Regression
  frequency: FREQUENT
  description: >-
    Loss of previously acquired skills including ambulation and independent
    feeding. Reported in 54% of the longitudinal cohort, rising with age from 30%
    of toddlers to 90% of adults, and a majority of adults lost gross and fine
    motor skills over a single year of follow-up.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The majority of probands (54%) had a history of parent-reported developmental regression that increased in prevalence across development with 30% of toddlers, 44% of children, 50% of adolescents, and 90% of adults experiencing prior regression.'
    explanation: '54 percent overall places this in the FREQUENT band; the age gradient, from 30 percent of toddlers to 90 percent of adults, is what marks it as progressive.'
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Adaptive functioning was longitudinally examined; a majority of adult participants (18+ years) lost gross and fine motor skills over a 1 year follow-up.'
    explanation: 'Quantifies the rate of loss in adults over a defined interval, which is stronger than a retrospective history.'
- category: Behavioral
  name: Autistic Behavior
  description: >-
    Autism spectrum disorder and hyperactivity are common and may resemble the
    behavioural profile of Angelman syndrome, which is the source of the
    long-standing diagnostic confusion between the two.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Behaviorally, autism spectrum disorder and hyperactivity are common, and may resemble
      the behaviors observed in Angelman syndrome.'
    explanation: States the behavioural phenotype and its resemblance to Angelman syndrome.
- category: Gastrointestinal
  name: Oropharyngeal Dysphagia
  description: >-
    Swallowing difficulty in infancy, which together with hypotonia may cause
    failure to thrive.
  phenotype_term:
    preferred_term: Oral-pharyngeal dysphagia
    term:
      id: HP:0200136
      label: Oral-pharyngeal dysphagia
  sequelae:
  - target: Failure to Thrive
    causal_link_type: DIRECT
    description: Impaired swallowing in infancy limits intake and produces poor weight gain.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Hypotonia and oropharyngeal dysphagia in infancy may result in failure to thrive.'
      explanation: States the causal link from dysphagia to failure to thrive directly.
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Hypotonia and oropharyngeal dysphagia in infancy may result in failure to thrive.'
    explanation: Names the dysphagia and its nutritional consequence.
- category: Growth
  name: Failure to Thrive
  description: >-
    Poor growth in infancy from feeding difficulty, and in the longitudinal cohort
    a persistently slow growth rate producing markedly reduced height and weight
    by adulthood.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The rate of growth across development was slow and resulted in prominently decreased age-normed height and weight by adulthood.'
    explanation: 'Extends the infantile feeding problem into a lifelong growth deficit measured relative to age norms.'
- category: Neurologic
  name: Cerebellar Atrophy
  frequency: FREQUENT
  description: >-
    Cerebellar atrophy on imaging, reported in 30 to 60% of patients and the
    structural correlate of the progressive ataxia.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: 'cerebellar degeneration in patients (atrophy in 30–60% of cases)'
    explanation: 'Gives the atrophy rate, supporting both the phenotype and the FREQUENT band. The whole 30 to 60 percent range falls inside the FREQUENT band (30 to 79 percent), with its lower end on the boundary; the 30 to 60 percent figure is the paper''s citation of earlier imaging series, not a measurement in its own cohort, hence BACKGROUND.'
- category: Neurologic
  name: Eye Movement Abnormality
  frequency: FREQUENT
  description: >-
    Abnormal eye movements, named among the defining neurologic findings and
    recorded in 68% of the longitudinal cohort, typically a unilateral inward
    deviation consistent with Duane anomaly.
  phenotype_term:
    preferred_term: Abnormality of eye movement
    term:
      id: HP:0000496
      label: Abnormality of eye movement
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'CLINICAL CHARACTERISTICS: Christianson syndrome (referred to as CS in this
      GeneReview), an X-linked disorder, is characterized in males by cognitive dysfunction,
      behavioral disorder, and neurologic findings (e.g., seizures, ataxia, postnatal
      microcephaly, and eye movement abnormalities).'
    explanation: Names eye movement abnormality among the four neurologic findings that
      characterise the disorder.
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Also noted is the unilateral inward deviation of the eye with eye movement abnormalities consistent with Duane anomaly; this was found in 68% of the current group'
    explanation: '68 percent of the cohort places this in the FREQUENT band.'
- category: Neurologic
  name: Hypotonia
  description: >-
    Infantile hypotonia, which together with the dysphagia is what produces the
    failure to thrive rather than a primary growth defect.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Hypotonia and oropharyngeal dysphagia in infancy may result in failure to thrive.'
    explanation: Names hypotonia in infancy and states its consequence, which is why it sits
      upstream of the failure to thrive already curated here.
- category: Neurologic
  name: Upper Motor Neuron Dysfunction
  frequency: FREQUENT
  description: >-
    Corticospinal tract signs in the majority of individuals over age ten,
    superimposed on the cerebellar picture. This matters to the entry's account of
    the course: the neurologic burden is not purely cerebellar, and the
    corticospinal component emerges with age.
  phenotype_term:
    preferred_term: Upper motor neuron dysfunction
    term:
      id: HP:0002493
      label: Upper motor neuron dysfunction
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'While neurologic examinations were consistent with cerebellar dysfunction, importantly, a majority of individuals (>50% older than 10) also had corticospinal tract abnormalities.'
    explanation: 'Gives both the proportion and the age dependence, and explicitly contrasts the corticospinal findings with the cerebellar ones.'
- category: Behavioral
  name: Unprovoked Laughter
  frequency: FREQUENT
  description: >-
    Laughter without an apparent trigger, reported in 62% of the longitudinal cohort; it was more common in adolescents and adults than in younger children, though the difference was not statistically significant. It has no incoming causal edge: the cohort study reports its frequency but proposes no mechanism, and no other source cited here addresses one.
  phenotype_term:
    preferred_term: Unprovoked laughter
    term:
      id: HP:0000748
      label: Inappropriate laughter
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2).'
    explanation: 'Gives unprovoked laughter at 62 percent, which is the FREQUENT band.'
- category: Skeletal
  name: Scoliosis
  frequency: FREQUENT
  description: >-
    Scoliosis in 39% of the longitudinal cohort, worsening with age and surgically corrected in some adolescents; GeneReviews surveillance includes assessment for scoliosis and kyphoscoliosis. It has no incoming causal edge: the cohort study reports its frequency but proposes no mechanism, and no other source cited here addresses one.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Scoliosis occurred in 39% of participants; two participants had corrective surgeries for scoliosis between 15 and 20 years of age.'
    explanation: 'Gives scoliosis at 39 percent, which is the FREQUENT band, and its surgical management in adolescence.'
- category: Gastrointestinal
  name: Gastroesophageal Reflux
  frequency: FREQUENT
  description: >-
    Current gastroesophageal reflux in 56% of the longitudinal cohort. It has no incoming causal edge: the cohort study reports its frequency but proposes no mechanism, and no other source cited here addresses one.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2).'
    explanation: 'Gives current GERD at 56 percent, which is the FREQUENT band.'
- category: Gastrointestinal
  name: Constipation
  frequency: FREQUENT
  description: >-
    Current constipation in 55% of the longitudinal cohort and in every adult participant, one of the clearest age-dependent medical burdens. It has no incoming causal edge: the cohort study reports its frequency but proposes no mechanism, and no other source cited here addresses one.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2).'
    explanation: 'Gives constipation at 55 percent, which is the FREQUENT band.'
- category: Neurologic
  name: Sleep Disturbance
  frequency: FREQUENT
  description: >-
    Current sleep problems in 51% of the longitudinal cohort. It has no incoming causal edge: the cohort study reports its frequency but proposes no mechanism, and no other source cited here addresses one.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2).'
    explanation: 'Gives current sleep problems at 51 percent, which is the FREQUENT band.'
- category: Ophthalmologic
  name: Reduced Visual Acuity
  frequency: FREQUENT
  description: >-
    Visual acuity problems in 52% of the longitudinal cohort, recorded separately from the eye movement abnormality. It has no incoming causal edge: the cohort study reports its frequency but proposes no mechanism, and no other source cited here addresses one.
  phenotype_term:
    preferred_term: Visual acuity problems
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2).'
    explanation: 'Gives visual acuity problems at 52 percent, which is the FREQUENT band.'
- category: Musculoskeletal
  name: Contractures
  frequency: FREQUENT
  description: >-
    Joint contractures in 36% of the longitudinal cohort. The source specifies neither the joints nor the direction, so the binding is the general joint-contracture class rather than a flexion or joint-specific term. It has no incoming causal edge: the cohort study reports its frequency but proposes no mechanism, and no other source cited here addresses one.
  phenotype_term:
    preferred_term: Contractures
    term:
      id: HP:0034392
      label: Joint contracture
  evidence:
  - reference: PMID:39237363
    reference_title: 'Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Secondary symptoms occurred in 35–84% of participants and included current sleep problems (51%), unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eye movement abnormalities (68%), regression (54%), swallowing problems (44%) and contractures (36%) (table 2).'
    explanation: 'Gives contractures at 36 percent, which is the FREQUENT band.'
genetic:
- name: SLC9A6
  gene_term:
    preferred_term: SLC9A6
    term:
      id: hgnc:11079
      label: SLC9A6
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Loss of Function, X-linked
  notes: >-
    Loss of function is the usual mechanism, but not the only one. A de novo
    missense variant in the ion translocation domain, p.Gly218Arg, behaves as a
    potential gain of function: it alkalinises rather than acidifies the endosome
    and still causes the core phenotype, while sparing the motor deterioration
    usually seen after the first decade. The gene is therefore better described as
    setting endosomal pH than as acidifying or alkalinising it.
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The diagnosis of CS is established in a male proband by identification of a hemizygous
      pathogenic variant in SLC9A6 on the X chromosome and in a female proband by identification
      of a heterozygous SLC9A6 pathogenic variant on molecular genetic testing.'
    explanation: States the causal relationship and the molecular diagnostic criterion.
  - reference: PMID:30296617
    reference_title: A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and
      neuronal atrophy associated with Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The patient manifested several core symptoms typical of CS, including pronounced
      cognitive impairment, mutism, epilepsy, ataxia and microcephaly; however, deterioration
      of motor function often observed after the first decade of life in CS children with total
      loss of SLC9A6/NHE6 function was not evident.'
    explanation: Documents the gain-of-function allele producing the core phenotype without the
      later motor deterioration, which is the basis for the allelic nuance in these notes.
inheritance:
- name: X-linked recessive
  description: >-
    X-linked. Affected males are hemizygous. Heterozygous females range from
    asymptomatic to mildly affected with intellectual disability or behavioural
    difficulty, and the mouse work indicates the variability tracks mosaic
    expression of the mutant allele under X-inactivation.
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Manifestations in heterozygous females range from asymptomatic to mild ID and/or
      behavioral issues.'
    explanation: States the range of expression in heterozygous females.
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Heterozygous (carrier) females have a 50% chance of transmitting the SLC9A6
      pathogenic variant in each pregnancy.'
    explanation: The recurrence risk that follows from X-linked inheritance, quantified. This is
      the operative number in counselling, from the GeneReviews GENETIC COUNSELING section.
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Sons who inherit the pathogenic variant will have CS; daughters who inherit the
      pathogenic variant may be asymptomatic or have mild ID and/or behavioral issues.'
    explanation: Splits the 50 percent transmission risk by sex of the offspring, which is what
      makes the figure actionable rather than abstract.
  - reference: PMID:26515654
    reference_title: 'X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic
      neuropathological changes and related behavioral abnormalities.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically
      distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous
      Slc9a6 KO female mice'
    explanation: Provides the mechanism for the variable female phenotype - mosaic expression
      producing mosaic pathology.
diagnosis:
- name: SLC9A6 molecular genetic testing
  presence: PRESENT
  description: >-
    The diagnosis is molecular. Clinical recognition is unreliable on its own
    because the phenotype overlaps Angelman syndrome closely enough that
    Christianson syndrome appears in the differential of Angelman-negative
    patients.
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The diagnosis of CS is established in a male proband by identification of a hemizygous
      pathogenic variant in SLC9A6 on the X chromosome and in a female proband by identification
      of a heterozygous SLC9A6 pathogenic variant on molecular genetic testing.'
    explanation: States the molecular diagnostic criterion for each sex.
  - reference: PMID:24779060
    reference_title: 'If not Angelman, what is it? A review of Angelman-like syndromes.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Angelman syndrome (AS) is caused by a lack of expression of the maternally inherited
      UBE3A gene in the brain. However, about 10% of individuals with a clinical diagnosis of
      AS do not have an identifiable molecular defect.'
    explanation: Establishes the Angelman-negative population in which this diagnosis is
      considered, which is the practical route to recognising it.
treatments:
- name: Seizure Management
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Anticonvulsant treatment per standard care. There is no disease-modifying
    therapy, and seizure control is among the treatment priorities caregivers name
    most often.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Treatment of manifestations: Management of neurodevelopmental disorders, feeding
      difficulties, and seizures are per standard care.'
    explanation: States that management is symptomatic and follows standard care rather than any
      disease-specific protocol.
  - reference: PMID:40170533
    reference_title: 'Christianson Syndrome Family Experiences: Results From Caregiver Interviews.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Caregivers emphasized connecting with other families and prioritized treatments for
      seizures, communication, and preventing regressions.'
    explanation: Records seizure control as a caregiver-stated treatment priority, which is the
      evidence that this target matters to patients rather than only to clinicians.
- name: Supportive and Nutritional Care
  therapeutic_modality: BEHAVIORAL
  description: >-
    Management of feeding difficulty and of the neurodevelopmental disorder, with
    surveillance of growth. Given the lifelong slow growth and the infantile
    dysphagia, nutrition is a recurring rather than a one-off problem.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Treatment of manifestations: Management of neurodevelopmental disorders, feeding
      difficulties, and seizures are per standard care.'
    explanation: Names feeding difficulty and neurodevelopmental management as the components of
      supportive care here.
- name: Regression Surveillance
  therapeutic_modality: OTHER
  description: >-
    Structured surveillance for skill loss in adolescents and young adults. This
    is the management recommendation that follows directly from the biphasic
    course this entry models: the developmental phase is not the whole disease,
    and the point of surveillance is to detect the degenerative phase when it
    starts rather than in retrospect.
  treatment_term:
    preferred_term: clinical evaluation for skill loss
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  target_mechanisms:
  - target: Developmental Regression
    treatment_effect: MODULATES
    description: Surveillance does not prevent regression. It changes when regression is
      recognised, which is what makes supportive intervention possible at all.
    evidence:
    - reference: PMID:29334451
      reference_title: Christianson Syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Detailed history and related assessments in adolescents and young adults for
        evidence of possible loss of any of the following skills: feeding, fine/gross motor
        skills, ambulation, and use of words/sounds.'
      explanation: Names the specific skills to be tracked, which are the same domains in which
        the longitudinal study documents measured loss.
  evidence:
  - reference: PMID:29334451
    reference_title: Christianson Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Surveillance: At the time of follow-up clinical examinations, the following are
      recommended: Measurement of weight and height (and calculation of body mass index).'
    explanation: Establishes that GeneReviews specifies a surveillance schedule rather than
      leaving follow-up unstructured.
animal_models:
- name: Nhe6-null mouse
  species: Mouse
  genotype: Slc9a6 knockout
  publication: PMID:29349289
  description: >-
    The principal model, and unusual in reproducing both halves of the human
    disease. Brain volume changes reflect undergrowth and tissue loss together,
    with Purkinje cell loss confirmed in two independent knockout lines.
  evidence:
  - reference: PMID:29349289
    reference_title: Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of
      Christianson Syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'We report PC loss in two distinct Nhe6-null mouse models.'
    explanation: Replication across two independent lines, which is why the finding is not treated
      as model-specific.
  modeled_mechanisms:
  - target: Progressive Neurodegeneration with Purkinje Cell Loss
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces progressive Purkinje cell loss beginning in the cerebellum, with
      wider cortical, hippocampal and striatal volume loss appearing later.
    limitations: >-
      Mice do not accumulate insoluble endogenous tau or amyloid-beta, so this
      model cannot address the tau deposition reported in human post-mortem
      material. That is what the rat model below was made for.
    evidence:
    - reference: PMID:29349289
      reference_title: Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of
        Christianson Syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'Reductions in volume are first apparent at 2 mo, particularly in the cerebellum,
        which demonstrates progressive loss of Purkinje cells (PCs).'
      explanation: Gives the timing and regional onset of the degeneration this link records.
  - target: Impaired Endosomal Maturation and Lysosomal Function
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the selective neuronal glycolipid and cholesterol storage with
      loss of beta-hexosaminidase activity, closely resembling a lysosomal storage
      disorder.
    limitations: >-
      The storage is regionally selective rather than global, so the model does not
      explain why particular neuronal populations are vulnerable.
    evidence:
    - reference: PMID:21964919
      reference_title: X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of
        endosomal-lysosomal dysfunction.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'we found that sodium-hydrogen exchanger 6 depletion leads to abnormal accumulation
        of GM2 ganglioside and unesterified cholesterol within late endosomes and lysosomes of
        neurons in selective brain regions'
      explanation: Documents the storage phenotype that this link records.
- name: NHE6-null rat
  species: Rat
  genotype: NHE6 null, CRISPR-Cas9
  publication: PMID:34928329
  description: >-
    Built specifically because mice do not deposit endogenous tau or amyloid-beta.
    The choice of species is itself the experimental design, which is worth noting
    because it means the tau result could not have been obtained in the mouse.
  evidence:
  - reference: PMID:34928329
    reference_title: Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in
      NHE6-null rat brain.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'Mouse models generally do not show the accumulation of insoluble,
      endogenously-expressed (non-transgenic) tau or amyloid-β.'
    explanation: States the limitation of the mouse that motivated building this model.
  modeled_mechanisms:
  - target: Progressive Neurodegeneration with Purkinje Cell Loss
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces early rapid Purkinje cell loss with a more protracted cerebral
      course, and establishes that the lysosomal defect precedes the
      neurodegeneration rather than following it.
    limitations: >-
      Ordering in a rodent lifespan does not establish the same ordering in a human
      course measured in decades.
    evidence:
    - reference: PMID:34928329
      reference_title: Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in
        NHE6-null rat brain.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'NHE6-null rats demonstrated an early and rapid loss of Purkinje cells in the
        cerebellum, as well as a more protracted neurodegenerative course in the cerebrum.'
      explanation: Gives the two-speed degeneration this link records.
- name: Heterozygous female Slc9a6 knockout mouse
  species: Mouse
  genotype: Slc9a6 KO heterozygous female, lacZ reporter
  publication: PMID:26515654
  description: >-
    Addresses the female carrier question directly by using a lacZ reporter
    knocked into the mutant allele, so X-inactivation can be visualised alongside
    the pathology it produces.
  evidence:
  - reference: PMID:26515654
    reference_title: 'X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic
      neuropathological changes and related behavioral abnormalities.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'In heterozygous female Slc9a6 KO mice, β-Gal serves as a transcriptional/XCI reporter
      and thus facilitates testing of effects of mosaic expression of the mutant allele on
      penetrance of the abnormal phenotype.'
    explanation: Describes the reporter design that makes mosaic expression directly observable.
  modeled_mechanisms:
  - target: Impaired Endosomal Maturation and Lysosomal Function
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the storage and Purkinje cell pathology in mosaic distribution,
      matching the partial and variable phenotype of human female carriers.
    limitations: >-
      Mouse X-inactivation patterns need not match human ones, so the model
      supports the mechanism of variability rather than predicting any individual
      carrier's severity.
    evidence:
    - reference: PMID:26515654
      reference_title: 'X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic
        neuropathological changes and related behavioral abnormalities.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically
        distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous
        Slc9a6 KO female mice'
      explanation: Documents the mosaic pathology this link records.
references:
- reference: PMID:21964919
  title: "X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of endosomal-lysosomal dysfunction."
- reference: PMID:24779060
  title: "If not Angelman, what is it? A review of Angelman-like syndromes."
- reference: PMID:26515654
  title: "X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic neuropathological changes and related behavioral abnormalities."
- reference: PMID:29334451
  title: "Christianson Syndrome."
  tags:
  - GeneReviews
- reference: PMID:29349289
  title: "Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of Christianson Syndrome."
- reference: PMID:30296617
  title: "A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and neuronal atrophy associated with Christianson Syndrome."
- reference: PMID:32107410
  title: "Sodium-hydrogen exchanger 6 (NHE6) deficiency leads to hearing loss, via reduced endosomal signalling through the BDNF/Trk pathway."
- reference: PMID:32569089
  title: "Loss of SLC9A6/NHE6 impairs nociception in a mouse model of Christianson syndrome."
- reference: PMID:34928329
  title: "Early lysosome defects precede neurodegeneration with amyloid-\u03b2 and tau aggregation in NHE6-null rat brain."
- reference: PMID:39237363
  title: "Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults."
- reference: PMID:39341363
  title: "Impaired hippocampal plasticity associated with loss of recycling endosomal SLC9A6/NHE6 is ameliorated by the TrkB agonist 7,8-dihydroxyflavone."
- reference: PMID:40170533
  title: "Christianson Syndrome Family Experiences: Results From Caregiver Interviews."
disease_term:
  preferred_term: Christianson syndrome
  term:
    id: MONDO:0010278
    label: Christianson syndrome
notes: >-
  Why the pathograph branches. This disorder is both neurodevelopmental and
  neurodegenerative in the same patient, and the two arms are modelled separately
  because they have different timing, different cellular substrates and different
  clinical consequences. The developmental arm runs through impaired arborisation
  and synaptogenesis to postnatal microcephaly and intellectual disability, and is
  fixed early. The degenerative arm runs through lysosomal failure and storage to
  Purkinje cell loss, progressive ataxia and regression, and continues through
  life. Collapsing them into one chain would lose the fact that a child can be
  developmentally static for a decade and then begin losing skills.

  Direction of the pH defect. NHE6 exports protons from the endosomal lumen, so
  losing it makes the compartment more acidic, not less. This is worth stating
  explicitly because the intuition runs the other way. The point is sharpened by
  p.Gly218Arg, a probable gain-of-function allele that alkalinises the endosome
  and still causes the core syndrome while sparing the later motor deterioration.
  Both directions are pathogenic, so the node is framed as loss of pH control.

  Where the chain stands. The BDNF-TrkB link is graded PROVISIONAL rather than
  HYPOTHETICAL, on the strength of a rescue experiment: the selective TrkB agonist
  7,8-dihydroxyflavone restores dendritic spine density and both functional and
  structural long-term potentiation in Nhe6-null hippocampal neurons. Rescue is
  much stronger evidence than the correlation available from the organ-of-Corti
  study, and it supplies the forebrain evidence that study could not. The edge
  onward to arborisation is still graded INDIRECT_UNKNOWN_INTERMEDIATES, because
  spine density and arborisation are related but not the same measurement.

  A second, pH-independent route. NHE6 also acts as a scaffold that recruits
  CDK5 and its activator p35 to endosomal and plasma membranes, raising cell
  surface accumulation of TRPV1. This matters because it means not every
  consequence of losing NHE6 needs to run through endosomal pH, and it supplies
  the mechanism for the pain phenotype specifically: Nhe6-null mice show reduced
  surface TRPV1 in nociceptors and blunted responses to noxious thermal,
  mechanical and chemical stimuli.

  Relationship to Angelman syndrome. The behavioural overlap is close enough that
  this disorder was originally described as X-linked Angelman-like syndrome, and
  the practical route to diagnosis is often a molecularly negative Angelman
  workup. Angelman syndrome is curated separately here; the two are distinct
  diseases with distinct genes and are not modelled as subtypes of one another.

  On prevalence. No quotable prevalence or incidence figure was found in the
  cached sources, and the deep-research report independently reached the same
  conclusion, describing precise prevalence and incidence as undefined and the
  condition as an under-recognised cause of X-linked intellectual disability. The
  absence is therefore recorded as a property of the literature rather than as a
  gap in this curation.

  Known extension points: AAV-mediated SLC9A6 gene replacement, which rescues
  motor and molecular phenotypes in the shaker rat and is the leading
  disease-modifying candidate; TrkB agonists and autophagy enhancers as further
  preclinical directions; the reported genotype-phenotype gradient in which null
  variants carry refractory epilepsy and loop-region missense variants a
  seizure-free course, which the 44-patient longitudinal cohort did not
  reproduce (it found no strong genotype-phenotype associations); a progression
  section, which the longitudinal data would support well given the documented
  age-dependence of microcephaly, ataxia, pain threshold and hyperkinesia;
  hearing loss, demonstrated in the mouse but not established as a human
  feature in these sources; and mortality, for which the cohort reports three
  deaths among 44 participants during the study period but no rate over a
  defined follow-up.

  Frequency bands for the core features. The six previously defined core
  criteria are banded VERY_FREQUENT from their per-feature rates in the
  longitudinal cohort (93 to 100 percent). None is banded OBLIGATE: the study
  states universal presence only within ages 6 to 16, and microcephaly, ataxia
  and high pain tolerance are less often present before age 6. The 30 to 60
  percent figure for cerebellar atrophy is an imaging rate cited from earlier
  series and bands only the Cerebellar Atrophy phenotype, not ataxia.


  Provenance. Curated from PubMed with a five-iteration OpenScientist
  deep-research job as a cross-check, recorded at
  research/Christianson_Syndrome-deep-research-openscientist.md. The
  natural-history figures come from the full text of the peer-reviewed report of
  the International Christianson Syndrome and NHE6 (SLC9A6) Gene Network Study
  (J Med Genet 2024, PMID:39237363), which supersedes its medRxiv preprint
  (PMID:37987014); the preprint is not cited. The preprint's Supplementary
  Table 1 stratifies the same symptoms by inheritance and mutation type, and its
  paired percentages (for example 43 and 76 percent for unprovoked laughter) are
  subgroup rates, not cohort-wide ones; the rates used here are the whole-cohort
  figures of the published paper.
📚

References & Deep Research

References

12
PMID:21964919
X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of endosomal-lysosomal dysfunction.
No top-level findings curated for this source.
PMID:24779060
If not Angelman, what is it? A review of Angelman-like syndromes.
No top-level findings curated for this source.
PMID:26515654
X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic neuropathological changes and related behavioral abnormalities.
No top-level findings curated for this source.
PMID:29334451
Christianson Syndrome.
No top-level findings curated for this source.
PMID:29349289
Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of Christianson Syndrome.
No top-level findings curated for this source.
PMID:30296617
A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and neuronal atrophy associated with Christianson Syndrome.
No top-level findings curated for this source.
PMID:32107410
Sodium-hydrogen exchanger 6 (NHE6) deficiency leads to hearing loss, via reduced endosomal signalling through the BDNF/Trk pathway.
No top-level findings curated for this source.
PMID:32569089
Loss of SLC9A6/NHE6 impairs nociception in a mouse model of Christianson syndrome.
No top-level findings curated for this source.
PMID:34928329
Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in NHE6-null rat brain.
No top-level findings curated for this source.
PMID:39237363
Christianson syndrome across the lifespan: genetic mutations and longitudinal study in children, adolescents, and adults.
No top-level findings curated for this source.
PMID:39341363
Impaired hippocampal plasticity associated with loss of recycling endosomal SLC9A6/NHE6 is ameliorated by the TrkB agonist 7,8-dihydroxyflavone.
No top-level findings curated for this source.
PMID:40170533
Christianson Syndrome Family Experiences: Results From Caregiver Interviews.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record notes

Why the pathograph branches. This disorder is both neurodevelopmental and neurodegenerative in the same patient, and the two arms are modelled separately because they have different timing, different cellular substrates and different clinical consequences. The developmental arm runs through impaired arborisation and synaptogenesis to postnatal microcephaly and intellectual disability, and is fixed early. The degenerative arm runs through lysosomal failure and storage to Purkinje cell loss, progressive ataxia and regression, and continues through life. Collapsing them into one chain would lose the fact that a child can be developmentally static for a decade and then begin losing skills. Direction of the pH defect. NHE6 exports protons from the endosomal lumen, so losing it makes the compartment more acidic, not less. This is worth stating explicitly because the intuition runs the other way. The point is sharpened by p.Gly218Arg, a probable gain-of-function allele that alkalinises the endosome and still causes the core syndrome while sparing the later motor deterioration. Both directions are pathogenic, so the node is framed as loss of pH control. Where the chain stands. The BDNF-TrkB link is graded PROVISIONAL rather than HYPOTHETICAL, on the strength of a rescue experiment: the selective TrkB agonist 7,8-dihydroxyflavone restores dendritic spine density and both functional and structural long-term potentiation in Nhe6-null hippocampal neurons. Rescue is much stronger evidence than the correlation available from the organ-of-Corti study, and it supplies the forebrain evidence that study could not. The edge onward to arborisation is still graded INDIRECT_UNKNOWN_INTERMEDIATES, because spine density and arborisation are related but not the same measurement. A second, pH-independent route. NHE6 also acts as a scaffold that recruits CDK5 and its activator p35 to endosomal and plasma membranes, raising cell surface accumulation of TRPV1. This matters because it means not every consequence of losing NHE6 needs to run through endosomal pH, and it supplies the mechanism for the pain phenotype specifically: Nhe6-null mice show reduced surface TRPV1 in nociceptors and blunted responses to noxious thermal, mechanical and chemical stimuli. Relationship to Angelman syndrome. The behavioural overlap is close enough that this disorder was originally described as X-linked Angelman-like syndrome, and the practical route to diagnosis is often a molecularly negative Angelman workup. Angelman syndrome is curated separately here; the two are distinct diseases with distinct genes and are not modelled as subtypes of one another. On prevalence. No quotable prevalence or incidence figure was found in the cached sources, and the deep-research report independently reached the same conclusion, describing precise prevalence and incidence as undefined and the condition as an under-recognised cause of X-linked intellectual disability. The absence is therefore recorded as a property of the literature rather than as a gap in this curation. Known extension points: AAV-mediated SLC9A6 gene replacement, which rescues motor and molecular phenotypes in the shaker rat and is the leading disease-modifying candidate; TrkB agonists and autophagy enhancers as further preclinical directions; the reported genotype-phenotype gradient in which null variants carry refractory epilepsy and loop-region missense variants a seizure-free course, which the 44-patient longitudinal cohort did not reproduce (it found no strong genotype-phenotype associations); a progression section, which the longitudinal data would support well given the documented age-dependence of microcephaly, ataxia, pain threshold and hyperkinesia; hearing loss, demonstrated in the mouse but not established as a human feature in these sources; and mortality, for which the cohort reports three deaths among 44 participants during the study period but no rate over a defined follow-up. Frequency bands for the core features. The six previously defined core criteria are banded VERY_FREQUENT from their per-feature rates in the longitudinal cohort (93 to 100 percent). None is banded OBLIGATE: the study states universal presence only within ages 6 to 16, and microcephaly, ataxia and high pain tolerance are less often present before age 6. The 30 to 60 percent figure for cerebellar atrophy is an imaging rate cited from earlier series and bands only the Cerebellar Atrophy phenotype, not ataxia. Provenance. Curated from PubMed with a five-iteration OpenScientist deep-research job as a cross-check, recorded at research/Christianson_Syndrome-deep-research-openscientist.md. The natural-history figures come from the full text of the peer-reviewed report of the International Christianson Syndrome and NHE6 (SLC9A6) Gene Network Study (J Med Genet 2024, PMID:39237363), which supersedes its medRxiv preprint (PMID:37987014); the preprint is not cited. The preprint's Supplementary Table 1 stratifies the same symptoms by inheritance and mutation type, and its paired percentages (for example 43 and 76 percent for unprovoked laughter) are subgroup rates, not cohort-wide ones; the rates used here are the whole-cohort figures of the published paper.

Create: Christianson Syndrome MONDO:0010278 · 2026-09-04T16:33:56Z · View source

Created from PubMed literature with a five-iteration OpenScientist deep-research job as a cross-check. The iteration count was chosen deliberately. A two-iteration run on the previous entry (aneurysmal bone cyst) produced three findings sections and no epidemiology at all, and missed five items a reviewer subsequently found in cached sources. This five-iteration run produced nine findings sections and 33 citations in 1059 seconds, against three sections and 29 citations in 757 seconds for two iterations. Roughly 40 percent more runtime for three times the structured findings. The report earned its place. It supplied a mechanism for a phenotype this entry had explicitly graded UNKNOWN. High pain tolerance is a core feature present in 91 percent of patients and the entry initially attached it to the graph with causal_link_type UNKNOWN, because no cached source proposed a mechanism. The report pointed to work showing NHE6 expression in nociceptors, reduced cell-surface TRPV1, and blunted nocifensive responses to thermal, mechanical and chemical stimuli in Nhe6-null mice. That was verified directly against PMID:32569089 before use and the edge was upgraded to INDIRECT_KNOWN_INTERMEDIATES. The report also surfaced a TrkB agonist rescue experiment (PMID:39341363) and a pH-independent CDK5 scaffolding role (PMID:42051037), both fetched and verified. The BDNF-TrkB node was consequently regraded from HYPOTHETICAL to PROVISIONAL. The original grading reflected that TrkB and Akt phosphorylation had been measured in the mouse organ of Corti, in a hearing-loss study, and extending that to forebrain arborisation was inference. The rescue experiment supplies the missing forebrain evidence: 7,8-dihydroxyflavone restores dendritic spine density and both functional and structural long-term potentiation in Nhe6-null hippocampal neurons. Rescue is stronger than correlation. The edge onward to arborisation remains INDIRECT_UNKNOWN_INTERMEDIATES because spine density and arborisation are related but not the same measurement. Two modelling decisions. First, the pathograph branches deliberately into a developmental arm (arborisation to postnatal microcephaly, intellectual disability, non-verbal status, epilepsy, hyperkinesia) and a degenerative arm (lysosomal storage to Purkinje cell loss, ataxia, regression, cerebellar atrophy). Collapsing them would lose the clinically important fact that a child can be developmentally static for a decade and then begin losing skills. Second, the direction of the pH defect is stated explicitly because intuition runs the other way: NHE6 exports protons, so losing it over-acidifies the endosome. The point is sharpened by p.Gly218Arg, a probable gain-of-function allele that alkalinises the endosome and still causes the core syndrome while sparing the later motor deterioration, so the node is framed as loss of pH control rather than as acidification. Process note. Four of the twelve cached references are full text rather than abstracts, and content_type in the cache frontmatter was checked before writing rather than after. The natural-history figures throughout come from reading those full texts. One artefact worth recording: PDF-derived full text carries interleaved line numbers that break sentences, so two snippets initially failed verification and were shortened to contiguous fragments. Topology was verified by parsing the file and printing every node with its outgoing edges. The first run found eight orphan phenotypes, which were connected before any commit. Final state: one root, no orphans, no dangling targets. On prevalence. No quotable prevalence or incidence figure exists in the cached sources, and the deep-research report independently reached the same conclusion, describing precise figures as undefined. The absence is recorded as a property of the literature rather than left as an unexplained gap. Validation: 59/59 snippets verified, term validation passes, weighted compliance 100.0 percent, all content gates clean.

OpenScientist ▸
Christianson Syndrome (MONDO:0010278): A Comprehensive Disease Characteristics Report
openscientist-autonomous 33 citations 2026-09-04T12:28:13.802112

Christianson Syndrome (MONDO:0010278): A Comprehensive Disease Characteristics Report

Disease: Christianson Syndrome (CS) · MONDO: MONDO:0010278 · OMIM: 300243 (MRXSCH — Intellectual disability, X-linked, syndromic, Christianson type) Gene: SLC9A6 (NHE6), Xq26.3 · HGNC: 11079 · NCBI Gene: 10479 · UniProt: Q92581

Summary

Christianson Syndrome (CS) is a rare X-linked recessive neurodevelopmental and neurodegenerative disorder of males caused by loss-of-function mutations in SLC9A6, the gene encoding the endosomal Na⁺/H⁺ exchanger NHE6. First delineated clinically by Christianson in 1999 and molecularly linked to SLC9A6 by Gilfillan et al. in 2008, CS presents with a highly stereotyped core phenotype: nonverbal status, severe intellectual disability, early-onset epilepsy, postnatal microcephaly, truncal ataxia, and hyperkinesia — a constellation present in >85% of affected males and universally present between ages 6 and 16. High pain tolerance was recently added as a seventh core diagnostic feature (present in ~91%). Because of striking clinical overlap with Angelman syndrome, cerebellar atrophy on MRI is an important discriminating feature that should prioritize SLC9A6 sequencing.

Mechanistically, CS is a disorder of endosomal pH homeostasis. NHE6 functions as a proton-leak pathway that counteracts the vacuolar H⁺-ATPase in early and recycling endosomes. Its loss causes over-acidification of the endosomal lumen, which produces two converging pathogenic arms: (1) attenuated BDNF/TrkB endosomal signaling, impairing axonal/dendritic arborization, synapse number, and circuit strength — the developmental arm that explains microcephaly and intellectual disability; and (2) endolysosomal and autophagic dysfunction, producing GM2 ganglioside and unesterified cholesterol storage, tau hyperphosphorylation, amyloid-β deposition, and progressive Purkinje-cell degeneration — the neurodegenerative arm that explains motor regression and Alzheimer-like pathology. A newly discovered pH-independent scaffolding function — recruitment of CDK5/p35 and promotion of cell-surface TRPV1 — provides a second molecular route to the sensory (pain) phenotype.

CS is currently managed supportively (anticonvulsants; physical/occupational/speech therapy; nutritional support). However, mechanistic understanding has generated strong preclinical disease-modifying candidates: AAV-mediated SLC9A6 gene replacement rescues cerebellar molecular and motor phenotypes in the shaker rat model; TrkB agonists (7,8-dihydroxyflavone) restore hippocampal plasticity; and autophagy enhancers (trehalose, rapamycin) rescue tau/lysosomal phenotypes in human iPSC neurons. The NHE6–endosomal-pH axis has also emerged as a convergent node in Alzheimer's disease via the ApoE4 → NHE6 → LRP1/amyloid-clearance pathway, giving CS translational relevance well beyond its own rarity.

Key Findings

Finding 1 — CS is an X-linked disorder caused by loss-of-function SLC9A6 mutations with a stereotyped core phenotype

Christianson Syndrome is caused by loss-of-function mutations in the X-linked gene SLC9A6, encoding the sodium/hydrogen exchanger NHE6. In the largest cohort to date — the International Christianson Syndrome and NHE6 Gene Network Study — 44 males carrying 31 unique NHE6 mutations were followed prospectively. Six core diagnostic criteria are present in >85% of patients and were universally present in individuals aged 6–16: nonverbal status, intellectual disability, epilepsy, postnatal microcephaly, ataxia, and hyperkinesia. This longitudinal study added a seventh core feature — high pain tolerance (present in 91%) — and found that >50% of individuals older than 10 also had corticospinal tract abnormalities superimposed on cerebellar dysfunction.

"Previously defined core diagnostic criteria for CS (present in >85%) - namely nonverbal status, intellectual disability, epilepsy, postnatal microcephaly, ataxia, hyperkinesia - were universally present in age 6 to 16; however, an additional core feature of high pain tolerance was added (present in 91%)" — PMID: 37987014

The mutational spectrum confirms a loss-of-function mechanism. In an earlier study of 12 pedigrees (14 boys), the spectrum comprised 9 single-nucleotide variants, 2 indels, and 1 copy-number-variant deletion — all protein-truncating or splicing mutations. Approximately 58% were de novo, with recurrent p.R500X and p.W570X alleles. Additional phenotype frequencies: eye-movement abnormalities ~79%, postnatal microcephaly ~92%, and cerebellar atrophy on MRI ~33% (up to ~60% in imaging-focused series).

"The mutational spectrum was composed of 9 single nucleotide variants, 2 indels, and 1 copy number variation deletion. All mutations were protein-truncating or splicing mutations." — PMID: 25044251

Finding 2 — Over-acidified endosomes attenuate BDNF/TrkB signaling and impair neuronal arborization (developmental arm)

The central developmental mechanism was established by Ouyang et al. (2013). Loss of NHE6 causes over-acidification of the endosomal compartment and attenuated TrkB signaling. NHE6-disrupted mouse brains show reduced axonal and dendritic branching, reduced synapse number, and reduced circuit strength. The proton-leak function of NHE6 is specifically required for arborization; TrkB (the BDNF receptor) colocalizes to NHE6-positive endosomes; and TrkB protein levels and phosphorylation are reduced after BDNF stimulation in mutant neurons. Critically, exogenous BDNF rescues the arborization defect, establishing that the mechanism is BDNF/TrkB-dependent and pharmacologically reversible.

"We demonstrate that loss of NHE6 results in overacidification of the endosomal compartment and attenuated TrkB signaling. Mouse brains with disrupted NHE6 display reduced axonal and dendritic branching, synapse number, and circuit strength." — PMID: 24035762

"Finally, exogenous BDNF rescues defects in neuronal arborization." — PMID: 24035762

Consistent with this, the TrkB agonist 7,8-dihydroxyflavone ameliorates impaired hippocampal plasticity associated with loss of NHE6 (PMID: 39341363), pointing to TrkB re-activation as a therapeutic strategy.

Finding 3 — Endolysosomal dysfunction drives storage, tau/amyloid pathology, and Purkinje-cell degeneration (neurodegenerative arm)

The second pathogenic arm is a progressive neurodegenerative cascade. In Slc9a6 knockout mice, NHE6 depletion leads to abnormal accumulation of GM2 ganglioside and unesterified cholesterol within late endosomes and lysosomes of neurons in selective brain regions (amygdala, hippocampal CA3/CA4/dentate, cortex), with undetectable β-hexosaminidase activity, neuroaxonal dystrophy, and progressive Purkinje-cell loss (Strømme et al. 2011).

"sodium-hydrogen exchanger 6 depletion leads to abnormal accumulation of GM2 ganglioside and unesterified cholesterol within late endosomes and lysosomes of neurons in selective brain regions" — PMID: 21964919

In human NHE6-knockout iPSC-derived cortical neurons, Fernandez et al. (2022) demonstrated elevated phosphorylated and sarkosyl-insoluble tau, reduced lysosomal number and protease activity, diminished autophagic flux, and p62 accumulation — phenotypes partially rescued by the autophagy enhancers trehalose or rapamycin.

"We report elevated phosphorylated and sarkosyl-insoluble tau in NHE6 KO neurons. We demonstrate that NHE6 KO leads to lysosomal and autophagy dysfunction involving reduced lysosomal number and protease activity, diminished autophagic flux, and p62 accumulation." — PMID: 36055242

In vivo, NHE6-null rats show an early, rapid loss of cerebellar Purkinje cells followed by a more protracted cerebral neurodegenerative course with endogenous amyloid-β and tau deposition (Lee et al. 2022).

"NHE6-null rats demonstrated an early and rapid loss of Purkinje cells in the cerebellum, as well as a more protracted neurodegenerative course in the cerebrum." — PMID: 34928329

Finding 4 — Genotype–phenotype correlation and TRPV1-based pain hyposensitivity

CS shows a genotype–phenotype gradient. Jiao et al. (2025) reported that among five hemizygous males, three null variants produced refractory epilepsy plus severe developmental delay; a missense variant in the transmembrane/pore region produced refractory epilepsy plus speech delay; and a missense variant in the loop region produced a seizure-free, favorable outcome. The proportions of brain atrophy, microcephaly, and movement disorders were significantly lower among missense-variant carriers than null-variant carriers.

"the proportions of brain atrophy, microcephaly, and movement disorders in patients with missense variants were significantly lower than that of patients with null variants, suggesting a genotype-phenotype correlation" — PMID: 40722028

The molecular basis of pain hyposensitivity was defined by Petitjean et al. (2020): Nhe6 KO mice have decreased nocifensive responses to noxious thermal, mechanical, and chemical (capsaicin) stimuli, and reduced capsaicin sensitivity correlates with decreased plasma-membrane TRPV1 expression and reduced capsaicin-induced Ca²⁺ influx in nociceptors.

"The reduced capsaicin sensitivity in the KO mice correlates with a decreased expression of the transient receptor potential channel TRPV1 at the plasma membrane and capsaicin-induced Ca influx in primary cultures of nociceptors." — PMID: 32569089

Finding 5 — AAV-mediated SLC9A6 gene replacement rescues the shaker rat, supporting gene therapy

Anderson et al. (2025–2026) used AAV vectors targeting Purkinje cells (PHP.eB-L7-Slc9a6-GFP) and a clinically relevant AAV9-CAG-hSLC9A6 construct in the shaker rat — a natural Slc9a6-mutant model of CS. Gene replacement produced significant improvement in both molecular and motor (ataxia, tremor) phenotypes in longitudinal studies, and the abundance of disease-relevant cerebellar proteins correlated strongly with motor ataxia.

"Administration of either of PHP.eB-L7-Slc9a6-GFP or AAV9-CAG-hSLC9A6 AAV vectors led to significant improvement in both the molecular and motor phenotypes." — PMID: 41934608

"Administration of either of PhP.eB-L7-Slc9a6-GFP or AAV9-CAG-hSLC9A6 AAV vectors led to significant improvement in the molecular and motor phenotypes." — PMID: 39868272

Complementary rescue strategies span the mechanism: autophagy enhancers (trehalose, rapamycin; PMID: 36055242), the TrkB agonist 7,8-DHF (PMID: 39341363), and vesicular de-acidification/protease inhibition (bafilomycin/leupeptin) that partially restore synaptic plasticity in vitro (PMID: 31175985).

Finding 6 — Female carriers show a graded phenotype; distinctive epilepsy syndromes; sensory GM2 storage in dorsal horn

Because of mosaic X-inactivation, female SLC9A6 carriers exhibit a graded neurological/psychiatric phenotype ranging from learning disability with speech difficulties to mild intellectual disability, with verbal/performance IQ dissociation, behavioral and psychiatric issues, and — in some — later parkinsonism/neurodegeneration (Masurel-Paulet 2016; Sinajon 2016; Pescosolido 2019).

"An abnormal phenotype, ranging from learning disability with predominant speech difficulties to mild intellectual deficiency, has been described previously in a large proportion of female car[riers]" — PMID: 27256868

CS epilepsy phenotypes include electrical status epilepticus during slow-wave sleep (ESES) and Lennox-Gastaut syndrome.

"epileptic encephalopathy with continuous spikes and waves during sleep" — PMID: 24630051

The sensory phenotype has an anatomical correlate: Kerner-Rossi et al. (2019) showed Slc9a6 KO mice have reduced responses to noxious thermal/mechanical stimuli with intracellular GM2 ganglioside accumulation most abundant in lamina I–II dorsal-horn neurons, plus astroglial/microglial changes.

"reduced behavioral responses to noxious thermal and mechanical stimuli (Hargreaves and Von Frey assays, respectively) compared to wild type (WT) littermates. Immunohistochemical and ultrastructural analysis of the spinal cord and peripheral nervous system revealed intracellular accumulation of the glycosphingolipid GM2 ganglioside" — PMID: 29772390

Finding 7 — Endosomal pH must be tightly balanced; NHE6 is a convergent node in Alzheimer's disease

Endosomal pH regulation is bidirectionally sensitive. Ilie et al. (2019) described a potential gain-of-function SLC9A6 variant that causes endosomal alkalinization and neuronal atrophy — demonstrating that both over-acidification (loss of function) and alkalinization (gain of function) are pathogenic (PMID: 30296617).

The same axis links CS to sporadic Alzheimer's disease. Prasad & Rao and colleagues showed the AD risk allele ApoE4 down-regulates NHE6, producing endosomal over-acidification that traps LRP1 intracellularly and impairs astrocytic amyloid-β clearance; NHE6 acts as a dominant proton-leak pathway and an ApoE4 effector.

"aberrant endosomal acidification in ApoE4 astrocytes traps the low-density lipoprotein receptor-related protein (LRP1) within intracellular compartments, leading to loss of surface expression and Aβ clearance" — PMID: 29946028

Huang et al. (2026) extended this therapeutically: targeting the HDAC4–NHE6–endosomal-pH axis with a BBB-penetrant HDAC inhibitor (vorinostat) restores NHE6 expression, endosomal pH, LRP1 surface expression, amyloid clearance, and cognition in 5xFAD mice (PMID: 41933339).

Finding 8 — SLC9A6/NHE6 gene and protein identity; ER-retention loss-of-function for some variants

NHE6/SLC9A6 is an X-linked gene (Xq26.3; HGNC:11079; NCBI Gene 10479; UniProt Q92581), widely expressed and especially abundant in brain, heart, and skeletal muscle, where it maintains endosomal pH homeostasis, trafficking, and cell polarity (Ilie et al. 2014).

"Na(+)/H(+) exchanger NHE6/SLC9A6 is an X-linked gene that is widely expressed and especially abundant in brain, heart and skeletal muscle where it is implicated in endosomal pH homeostasis and trafficking as well as maintenance of cell polarity" — PMID: 24090639

Even some in-frame variants are loss-of-function via mistrafficking. The ΔWST (Δ370Trp-Ser-Thr372) in-frame deletion adjoining the 9th transmembrane helix is synthesized but shows dramatically reduced oligosaccharide maturation and half-life, accumulates in the ER, and traffics negligibly to recycling endosomes.

"the mutant protein was effectively synthesized, but its subsequent oligosaccharide maturation and overall half-life were dramatically reduced compared to wild-type. These changes correlated with significant accumulation of ΔWST in the endoplasmic reticulum" — PMID: 24090639

Finding 9 — NHE6 also acts as a pH-independent scaffold recruiting CDK5/p35 and promoting surface TRPV1

Flessner et al. (2026) used a yeast two-hybrid screen against the NHE6 cytoplasmic C-terminus and identified CDK5 as an interacting partner, confirmed biochemically and by microscopy in CHO AP-1 and SH-SY5Y cells. CDK5 (with activator p35/CDK5R1) did not phosphorylate or regulate NHE6 trafficking; instead, NHE6 expression enhanced localization of CDK5 and p35 to endosomal/plasmalemmal membranes and elevated cell-surface accumulation of the CDK5-regulated TRPV1 channel.

"we describe a new role for NHE6 as a scaffolding platform for recruiting and delivering signaling molecules to the plasma membrane" — PMID: 42051037

"NHE6 expression enhanced the localization of CDK5 and p35 to endosomal- and plasmalemmal-enriched membrane fractions and elevated cell surface accumulation of the CDK5-regulated transient receptor potential V1 (TRPV1) cation channel" — PMID: 42051037

This is a pH-independent second hit that converges on the same sensory pathway (surface TRPV1) implicated in the pain phenotype (Finding 4).

Full Section-by-Section Report

1. Disease Information

Overview. Christianson Syndrome is an X-linked recessive syndromic intellectual-disability disorder (X-linked intellectual disability, syndromic, Christianson type; MRXSCH) with prominent neurodevelopmental and later neurodegenerative components. Affected males are nonverbal with severe/profound intellectual disability, develop early-onset epilepsy, postnatal microcephaly, truncal ataxia, hyperkinesia, ophthalmologic (eye-movement) abnormalities, and high pain tolerance. Its clinical overlap with Angelman syndrome (happy demeanor, absent speech, seizures, ataxic gait, microcephaly) is a recurring diagnostic pitfall; cerebellar atrophy/cerebellar cortical hyperintensity on MRI is relatively specific for CS and should prioritize SLC9A6 sequencing (PMID: 24285247).

Key identifiers:

Resource Identifier
MONDO MONDO:0010278
OMIM 300243 (MRXSCH / Christianson type)
Gene SLC9A6 (OMIM 300231)
MeSH Christianson syndrome / Intellectual disability, X-linked
Category X-linked neurodevelopmental disorder

Synonyms / alternative names: Christianson type X-linked intellectual disability; MRXSCH; X-linked intellectual disability, syndromic, Christianson type; Angelman-like syndrome, X-linked; NHE6 deficiency; SLC9A6-related intellectual disability.

Source of information: Predominantly aggregated disease-level resources plus individual patient case reports and prospective cohort studies (e.g., the International Christianson Syndrome and NHE6 Gene Network Study, PMID: 37987014; PMID: 39237363).

2. Etiology

Causal factor: Monogenic — hemizygous loss-of-function mutations in SLC9A6 in males. There are no established environmental, infectious, or toxic causes.

Genetic risk factors: The single causal locus is SLC9A6. Pathogenic variants are overwhelmingly protein-truncating (nonsense, frameshift) or splice-altering (PMID: 25044251); a minority are missense or in-frame indels that cause loss of function through mistrafficking/ER retention (PMID: 24090639) or reduced transport activity. ~58% of variants are de novo; recurrent alleles include p.R500X and p.W570X.

Environmental risk factors: None identified. The dominant demographic risk factor is being male (hemizygous); female carriers have milder, mosaic phenotypes.

Protective factors: No established protective variants or exposures. Within-gene, missense/hypomorphic variants confer a milder phenotype relative to null variants (PMID: 40722028) — a genotype-relative protective effect rather than an external protective factor.

Gene–environment interactions: Not established for CS itself. A conceptually related interaction exists in Alzheimer's disease, where the ApoE4 genotype down-regulates NHE6 (PMID: 29946028, PMID: 32737755).

3. Phenotypes

Phenotype Type HPO (suggested) Onset Frequency Progression
Nonverbal / absent speech Cognitive/behavioral HP:0001344 Childhood >85% (universal 6–16) Non-developing
Intellectual disability (severe/profound) Cognitive HP:0010864 Childhood >85% Regression
Epilepsy / seizures Clinical sign HP:0001250 Early childhood >85% Often refractory
Postnatal microcephaly Physical HP:0005484 Postnatal (>~12 mo) ~92% Progressive
Ataxia / truncal ataxia Clinical sign HP:0001251 / HP:0002078 Childhood >85% Progressive
Hyperkinesia Clinical sign HP:0002487 Childhood >85% Variable
High pain tolerance Sensory HP:0007021 Childhood ~91% Stable
Eye-movement abnormality / ophthalmoplegia Clinical sign HP:0000496 Childhood ~79% —
Cerebellar atrophy (MRI) Imaging HP:0001272 After 12 mo ~33–60% Progressive
Hypotonia→spasticity, ataxic gait Clinical sign HP:0001256 / HP:0001257 Childhood Common Progressive
Corticospinal tract abnormalities Clinical sign HP:0002493 >10 yr >50% (>10 yr) Progressive
Failure to thrive / low weight Physical HP:0001508 Childhood Common Progressive
Autistic-like behavior Behavioral HP:0000729 Childhood Common —
Retinitis pigmentosa (rare) Physical HP:0000510 Late Rare Progressive

Severity/progression overview: Severe disorder with a biphasic course — a developmental phase (microcephaly, intellectual disability, epilepsy) followed by neurodegenerative regression in adolescence/adulthood (loss of gross and fine motor skills; PMID: 39237363).

Quality-of-life impact: Profound. Nonverbal status, intellectual disability, refractory epilepsy, ataxia, and motor regression render patients fully dependent for daily activities; feeding difficulties and low weight add nutritional burden. Formal QoL instrument (EQ-5D/SF-36) data specific to CS are not available.

4. Genetic / Molecular Information

Causal gene: SLC9A6 (NHE6), Xq26.3; HGNC:11079; NCBI Gene 10479; UniProt Q92581; OMIM gene 300231. Encodes a multipass transmembrane Na⁺(K⁺)/H⁺ exchanger functional in early and recycling endosomes (PMID: 24090639).

Pathogenic variants: - Type/class: Predominantly nonsense, frameshift, and splice-site (all protein-truncating or splicing in the 12-pedigree spectrum; PMID: 25044251). Also missense and in-frame indels (e.g., ΔWST/Δ370-372; ΔES/p.E287-S288del). - Recurrent alleles: p.R500X, p.W570X; recurrent splice variants (e.g., c.1463-1G>A → exon 12 skipping, PMID: 34791706). - ACMG classification: Truncating variants are Pathogenic (PVS1). Missense variants require functional assessment; a framework exists (PMID: 31676550). - Allele frequency: Essentially absent from gnomAD (constrained X-linked gene; pathogenic variants private/de novo). - Origin: Germline; ~58% de novo, remainder inherited from carrier mothers. - Functional consequence: Predominantly loss of function (loss of proton-leak/exchange activity, protein instability, ER retention/mistrafficking). A rare gain-of-function variant causing endosomal alkalinization is documented (PMID: 30296617).

Modifier genes: No formal modifier loci identified. Severity tracks intrinsic variant class (null vs missense/hypomorphic; PMID: 40722028).

Epigenetic information: Not directly implicated in CS pathogenesis. Relevant upstream regulation exists — HDAC-mediated transcriptional control of NHE6 (PMID: 29567836) and HDAC4-driven repression in AD (PMID: 41933339).

Chromosomal abnormalities: Rare CNV deletions of SLC9A6 (1 of 12 pedigrees in PMID: 25044251); no recurrent large rearrangements characteristic of the disorder.

5. Environmental Information

No environmental factors, lifestyle factors, or infectious agents are known to cause or trigger Christianson Syndrome. It is a purely monogenic disorder. (Not applicable for this disease.)

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. A loss-of-function mutation in SLC9A6 (truncating, splice, or mistrafficking missense/indel) leads to absent or non-functional NHE6 protein in early/recycling endosomes. (demonstrated)
  2. Loss of the NHE6 proton-leak pathway results in unopposed V-ATPase activity and over-acidification of the endosomal lumen. (demonstrated — PMID: 24035762, PMID: 37747131)
  3. Endosomal over-acidification branches into three arms:

Arm A — Developmental / signaling: 3A. Over-acidification attenuates TrkB endosomal signaling (reduced TrkB level and BDNF-stimulated phosphorylation). (demonstrated — PMID: 24035762) 4A. Attenuated BDNF/TrkB signaling leads to reduced axonal/dendritic arborization, fewer synapses, weaker circuits. (demonstrated; rescued by BDNF and TrkB agonist 7,8-DHF) 5A. Impaired neurodevelopment results in postnatal microcephaly, intellectual disability, nonverbal status, and contributes to epilepsy. (inferred from model→human correspondence)

Arm B — Endolysosomal / degenerative: 3B. Over-acidification and disrupted trafficking impair endolysosomal maturation and autophagic flux (reduced lysosomal number/protease activity, p62 accumulation). (demonstrated — PMID: 36055242) 4B. Endolysosomal dysfunction leads to GM2 ganglioside and unesterified cholesterol storage, plus hyperphosphorylated/insoluble tau and amyloid-β. (demonstrated — PMID: 21964919, PMID: 34928329) 5B. Proteostatic/lipid stress results in neuroaxonal dystrophy and progressive Purkinje-cell degeneration and cerebral neurodegeneration. (demonstrated in rodent models) 6B. Cerebellar/cerebral degeneration leads to ataxia, motor regression, cerebellar atrophy on MRI. (inferred from model→human correspondence)

Arm C — pH-independent scaffolding (sensory): 3C. Loss of NHE6 also removes a scaffolding platform that recruits CDK5/p35 to membranes and promotes surface delivery of TRPV1. (demonstrated in vitro — PMID: 42051037) 4C. Reduced surface TRPV1 (plus GM2 storage in dorsal-horn nociceptive neurons) results in high pain tolerance / nociceptive impairment. (demonstrated in KO mice — PMID: 32569089, PMID: 29772390)

   SLC9A6 LoF mutation
          │
   Absent/nonfunctional NHE6 (endosome)
          │
   Endosomal over-acidification ───────────────┐ (also: scaffolding loss)
     │                    │                     │
  [Arm A]              [Arm B]               [Arm C]
  ↓ TrkB signaling    ↓ autophagy/lysosome   ↓ CDK5/p35 recruitment
  ↓ arborization      GM2/cholesterol store   ↓ surface TRPV1
  ↓ synapses          tau/Aβ pathology        ↓ nociception
     │                Purkinje-cell death        │
  microcephaly, ID,   ataxia, regression,     high pain
  nonverbal, epilepsy cerebellar atrophy      tolerance

Molecular pathways: BDNF–TrkB (NTRK2) neurotrophin signaling (KEGG hsa04722); endocytosis/endosomal recycling (KEGG hsa04144); autophagy–lysosome (KEGG hsa04140); sphingolipid metabolism (GM2). Cellular processes: endosomal acidification, receptor recycling, macroautophagy, apoptosis/neurodegeneration, synaptic plasticity. Protein dysfunction: loss of ion-exchange function, protein instability, ER retention/misfolding (PMID: 24090639). Metabolic changes: glycosphingolipid (GM2) and cholesterol storage; secondary β-hexosaminidase deficiency. Immune involvement: reactive astrogliosis/microgliosis accompanying storage (PMID: 29772390) — secondary, not autoimmune. Tissue damage: proteostatic/lysosomal stress and neuroaxonal dystrophy.

Suggested GO / CL terms: GO:0006886 (intracellular protein transport), GO:0051453 (regulation of intracellular pH), GO:0006914 (autophagy), GO:0038179 (neurotrophin signaling), GO:0048813 (dendrite morphogenesis). Cellular component: GO:0055037 (recycling endosome), GO:0005768 (endosome), GO:0005765 (lysosomal membrane), GO:0005783 (endoplasmic reticulum). Cell types: CL:0000121 (Purkinje cell), CL:0000540 (neuron), CL:0000679 (glutamatergic neuron), CL:0000127 (astrocyte), CL:0000129 (microglial cell).

7. Anatomical Structures Affected

  • Primary organ: Brain (nervous system). Secondary: peripheral/sensory nervous system; growth (weight/height).
  • Body systems: Central nervous system (predominant), with cerebellar and corticospinal (motor) systems.
  • Specific regions (UBERON): cerebellum (UBERON:0002037) — especially Purkinje-cell layer; hippocampus (UBERON:0002421, CA3/CA4/dentate); cerebral cortex (UBERON:0000956); amygdala (UBERON:0001876); basal ganglia (elevated glutamate/glutamine on MRS); brainstem/corticospinal tracts; spinal cord dorsal horn lamina I–II (UBERON:0002240); retina (UBERON:0000966) in rare cases.
  • Tissue/cell level: Nervous tissue; Purkinje cells (CL:0000121) are the most vulnerable population; hippocampal and cortical pyramidal neurons; dorsal-horn nociceptive neurons; reactive astrocytes and microglia.
  • Subcellular (GO cellular component): recycling endosome (GO:0055037), early endosome (GO:0005769), late endosome/lysosome (GO:0005764/GO:0005765), endoplasmic reticulum (GO:0005783, for mistrafficked variants), plasma membrane (TRPV1).
  • Lateralization: Bilateral, symmetric CNS involvement.

8. Temporal Development

  • Onset: Congenital/infantile developmental delay; postnatal microcephaly (normal head circumference at birth, decelerating after ~12 months); seizures typically begin in early childhood. Onset pattern is insidious/chronic.
  • Progression: Biphasic — early neurodevelopmental phase followed by progressive neurodegeneration in adolescence and adulthood, with loss of gross and fine motor skills documented over a 1-year follow-up in adults (PMID: 39237363). Cerebellar atrophy and motor regression are hallmark degenerative features (PMID: 22541666).
  • Disease course: Chronic, lifelong, progressive. No remissions.
  • Critical periods: The neurodevelopmental window (infancy–childhood, when BDNF/TrkB-dependent arborization occurs) is the key intervention window for the developmental arm; earlier gene replacement or TrkB agonism is predicted to be more effective, though the degenerative arm may permit later intervention.

9. Inheritance and Population

  • Inheritance: X-linked recessive; affected males, carrier females with variable mosaic expression.
  • Epidemiology: Rare; precise prevalence/incidence undefined. CS is considered an under-recognized cause of X-linked intellectual disability (frequently misdiagnosed as Angelman syndrome). Orphanet lists it as a rare disease.
  • Penetrance: Complete in hemizygous males; variable/incomplete and graded in heterozygous females (X-inactivation-dependent).
  • Expressivity: Variable, correlating with variant class (null > missense; PMID: 40722028) and, in females, degree of skewed X-inactivation (PMID: 26515654).
  • Genetic anticipation: Not applicable (not a repeat-expansion disorder).
  • Mosaicism: ~58% de novo; carrier mothers may transmit; germline mosaicism possible.
  • Founder effects / consanguinity / carrier frequency: No founder effect; not consanguinity-driven (X-linked); carrier frequency very low.
  • Demographics: No ethnic/geographic predilection; reported worldwide (European, Chinese, Japanese, etc.). Sex ratio: overwhelmingly males affected; females typically milder carriers.

10. Diagnostics

  • Genetic testing (definitive): Diagnosis rests on identifying a pathogenic SLC9A6 variant. Whole-exome sequencing (WES) and multigene intellectual-disability/epilepsy panels are the mainstay; single-gene sequencing of SLC9A6 is appropriate when CS is clinically suspected (Angelman-like phenotype + cerebellar atrophy). Chromosomal microarray detects rare CNV deletions. Minigene/RNA assays confirm splice variants (PMID: 34791706, PMID: 37213903). Functional assays assess missense VUS (PMID: 31676550).
  • Imaging: MRI shows cerebellar atrophy (developing after 12 months) and cerebellar-cortical hyperintensity — relatively specific and useful to distinguish from Angelman syndrome (PMID: 24285247). MRS shows elevated glutamate/glutamine in basal ganglia (PMID: 20949524).
  • Electrophysiology: EEG characterizes epilepsy phenotypes including ESES (PMID: 24630051) and Lennox-Gastaut syndrome (PMID: 31879735).
  • Biomarkers: No validated circulating biomarker. Research-level markers include endosomal pH, GM2 accumulation, and tau/Aβ in models.
  • Clinical criteria: Core diagnostic criteria (>85%): nonverbal, intellectual disability, epilepsy, postnatal microcephaly, ataxia, hyperkinesia; plus high pain tolerance (91%) (PMID: 37987014).
  • Differential diagnosis: Angelman syndrome (primary DDx — distinguished by SLC9A6 genetics and cerebellar atrophy), Rett/MECP2 disorders, Mowat-Wilson, other X-linked intellectual disabilities, mitochondrial disorders, and neuronal ceroid lipofuscinoses.
  • Screening: No newborn screening. Carrier testing and cascade screening in families with a known variant; prenatal/preimplantation testing available.

11. Outcome / Prognosis

  • Survival/mortality: Life expectancy is reduced; natural history includes progressive neurodegeneration. In the international longitudinal cohort, 3 participants died during the study period (PMID: 39237363). Precise mortality rates are not established; deaths relate to epilepsy, aspiration, and complications of severe disability.
  • Morbidity/function: Severe lifelong disability — nonverbal, dependent for all activities of daily living, with adult motor regression.
  • Growth: Slow growth across development, with prominently decreased age-normed height and weight by adulthood (PMID: 39237363).
  • Complications: Refractory epilepsy, feeding difficulties/failure to thrive, aspiration, orthopedic sequelae of ataxia/spasticity, progressive motor decline.
  • Prognostic factors: Variant class is the strongest determinant — null variants predict more severe disease (brain atrophy, microcephaly, movement disorders) than missense variants (PMID: 40722028).

12. Treatment

Current care is supportive; no approved disease-modifying therapy exists.

  • Pharmacotherapy (symptomatic): Antiseizure medications for epilepsy (individualized; Lennox-Gastaut/ESES often refractory). NCIT: Anticonvulsant Agent. Management of movement disorder, sleep, behavior, and GI/nutrition.
  • Supportive/rehabilitative: Physical, occupational, and speech/communication therapy; nutritional support (gastrostomy if needed); orthopedic and ophthalmologic care. NCIT: Physical Therapy, Occupational Therapy, Speech and Language Therapy, Supportive Care.
  • Experimental / disease-modifying (preclinical):
  • Gene replacement: AAV-mediated SLC9A6 delivery (PHP.eB-L7-Slc9a6-GFP; AAV9-CAG-hSLC9A6) rescues molecular and motor phenotypes in the shaker rat (PMID: 41934608, PMID: 39868272). NCIT: Gene Therapy.
  • TrkB agonism: 7,8-dihydroxyflavone ameliorates hippocampal plasticity deficits (PMID: 39341363); exogenous BDNF rescues arborization (PMID: 24035762).
  • Autophagy enhancers: Trehalose and rapamycin partially rescue tau/lysosomal phenotypes in human iPSC neurons (PMID: 36055242).
  • Endosomal pH modulation: Bafilomycin (vesicular de-acidification) and leupeptin (protease inhibition) partially restore synaptic plasticity in vitro (PMID: 31175985); HDAC inhibition can up-regulate NHE6 where residual expression exists (PMID: 29567836).
  • Personalized medicine: Variant-specific responses to rescue strategies are documented in iPSC neurons (PMID: 33568516), supporting genotype-guided therapy selection (gene replacement for null variants; chaperone/trafficking correction for ER-retained missense variants).

13. Prevention

  • Primary prevention: Not possible for a de novo/germline monogenic disorder. Genetic counseling for at-risk families is central: carrier mothers have 50% transmission risk to sons.
  • Secondary prevention: No population screening. Carrier and cascade testing in known families; prenatal diagnosis and preimplantation genetic testing available where a familial variant is known.
  • Tertiary prevention: Optimized seizure control, aspiration precautions, nutritional and orthopedic management to prevent complications.
  • Counseling: Genetic counseling per NSGC/ACMG principles; recurrence-risk assessment.

14. Other Species / Natural Disease

  • Taxonomy / orthologs: Homo sapiens SLC9A6 (Gene 10479); Mus musculus Slc9a6; Rattus norvegicus Slc9a6. NHE6 is evolutionarily conserved across vertebrates.
  • Natural disease model: The shaker rat is a spontaneous Slc9a6-mutant rat exhibiting cerebellar Purkinje-cell degeneration, ataxia, and tremor — a naturally occurring animal model of CS used for gene-therapy studies (PMID: 41934608, PMID: 39868272).
  • Comparative biology: Rodent models recapitulate endolysosomal storage, Purkinje-cell loss, tau/amyloid pathology, and pain insensitivity, indicating strong evolutionary conservation of the disease mechanism.
  • Zoonotic potential: None (non-infectious, genetic).

15. Model Organisms

Model Type Genetic strategy Key phenotypes recapitulated Reference
Slc9a6 KO mouse Mammalian Knockout (lacZ into exon 6) Endosomal-lysosomal dysfunction, GM2/cholesterol storage, Purkinje-cell degeneration, motor/memory deficits PMID: 21964919
Heterozygous female Slc9a6 KO mouse Mammalian Heterozygous KO Mosaic neuropathology and behavioral deficits (models female carriers) PMID: 26515654
Nhe6 KO mouse (nociception) Mammalian Knockout Reduced thermal/mechanical/chemical nociception; ↓ surface TRPV1; dorsal-horn GM2 storage PMID: 32569089, PMID: 29772390
NHE6-null rat Mammalian Knockout Early Purkinje-cell loss; later cerebral neurodegeneration with Aβ and tau PMID: 34928329
shaker rat Mammalian (natural) Spontaneous Slc9a6 mutation Cerebellar degeneration, ataxia, tremor; used for AAV gene therapy PMID: 41934608
Human CS iPSC-derived neurons In vitro (human) Patient-derived / CRISPR KO Endosomal over-acidification, ↑ p-tau, lysosomal/autophagy dysfunction; mutation-specific rescue PMID: 36055242, PMID: 33568516
Hap1 haploid NHE6-null cells In vitro (human) CRISPR/Cas9 LoF Intra-endosomal over-acidification; transcriptomic lysosome/neurodevelopment signatures PMID: 37747131

Applications: These models enable study of endosomal-pH regulation, BDNF/TrkB signaling, autophagy-lysosome biology, Purkinje-cell degeneration, nociception, and preclinical testing of gene replacement, TrkB agonists, and autophagy enhancers. Limitations: Rodent lifespan limits modeling of the slow human adult neurodegenerative course; behavioral readouts imperfectly capture nonverbal cognition; iPSC neurons lack circuit-level and glial context.

Mechanistic Model / Interpretation

Christianson Syndrome is best understood as a single upstream lesion (endosomal pH dysregulation) that fans out into three downstream arms. NHE6 normally leaks protons out of endosomes to keep luminal pH in a permissive window. When NHE6 is lost, endosomes over-acidify. This one biophysical change simultaneously (A) silences neurotrophin (BDNF/TrkB) signaling that neurons depend on to grow and wire — explaining the developmental phenotypes (microcephaly, intellectual disability, epilepsy); (B) clogs the endolysosomal–autophagy machinery, producing lipid/glycolipid storage, tau and amyloid pathology, and death of the exquisitely vulnerable cerebellar Purkinje cell — explaining the degenerative phenotypes (ataxia, motor regression, cerebellar atrophy); and (C), through a pH-independent scaffolding role, fails to deliver CDK5/p35 and TRPV1 to the membrane — explaining the sensory phenotype (high pain tolerance), reinforced by GM2 storage in dorsal-horn neurons.

The bidirectional pH principle (both over-acidification from loss of function and alkalinization from a gain-of-function variant are pathogenic) shows the system is tuned to a narrow set-point. The ApoE4 → NHE6 → LRP1/amyloid axis extends the same principle to common Alzheimer's disease, making NHE6 a rare-to-common disease bridge and a shared therapeutic target.

Therapeutically, the model predicts — and preclinical data confirm — that each arm is druggable: gene replacement restores the whole system upstream (most complete rescue); TrkB agonists target Arm A; autophagy/lysosome enhancers target Arm B. Convergence of independent rescue strategies onto the same mechanism is the strongest validation of the causal model.

Evidence Base

PMID Contribution Evidence type
37987014 / 39237363 Core diagnostic criteria, natural history, mortality Human clinical cohort
25044251 LoF mutational spectrum, de novo rate Human genetics
24035762 Over-acidification → ↓TrkB → ↓arborization; BDNF rescue Mouse / in vitro
21964919 GM2/cholesterol storage; Purkinje degeneration Mouse
36055242 Tau pathology, autophagy defect; trehalose/rapamycin rescue Human iPSC
34928329 Early lysosome defect → Aβ/tau neurodegeneration Rat
40722028 Genotype–phenotype (null vs missense) Human clinical
32569089 / 29772390 Pain hyposensitivity via ↓surface TRPV1 & dorsal-horn GM2 Mouse
41934608 / 39868272 AAV SLC9A6 gene replacement rescues shaker rat Rat / gene therapy
30296617 Gain-of-function alkalinization also pathogenic In vitro
29946028 / 41933339 ApoE4/HDAC4–NHE6–LRP1 axis in Alzheimer's Mouse / astrocyte
24090639 Gene/protein identity; ER-retention LoF mechanism In vitro
42051037 pH-independent CDK5/p35 scaffolding, surface TRPV1 In vitro
39341363 TrkB agonist 7,8-DHF rescues plasticity Mouse
31175985 ΔES mutation; bafilomycin/leupeptin partial rescue In vitro
33568516 Mutation-specific rescue responses Human iPSC
24285247 Cerebellar atrophy distinguishes CS from Angelman Human imaging

Limitations and Knowledge Gaps

  1. Epidemiology is undefined — true prevalence/incidence unknown; CS is under-diagnosed and often mistaken for Angelman syndrome.
  2. No validated fluid biomarker exists for diagnosis or monitoring; endosomal pH and storage markers remain research tools.
  3. Human trial data are absent — all disease-modifying evidence (gene therapy, TrkB agonists, autophagy enhancers) is preclinical (rodent/iPSC).
  4. Therapeutic window uncertainty — the relative contribution and reversibility of the developmental vs degenerative arms at different ages is unresolved, affecting when intervention is most effective.
  5. Female carrier phenotype is incompletely characterized; the quantitative relationship between X-inactivation skewing and severity needs definition.
  6. The scaffolding (CDK5/TRPV1) mechanism is in-vitro only and needs in-vivo and human validation.
  7. One citation ([PMID: 30296617], gain-of-function variant) was flagged as a title/abstract mismatch during curation and should be re-verified against the primary abstract before knowledge-base use.

Proposed Follow-up Experiments / Actions

  1. Establish a CS natural-history registry with standardized motor/cognitive and MRI-volumetric endpoints to define trajectories and support trial design.
  2. Advance AAV9-CAG-hSLC9A6 toward IND — dose-ranging, biodistribution, and age-of-treatment studies in shaker rats and Slc9a6-KO mice to define the therapeutic window.
  3. Develop fluid/imaging biomarkers — CSF tau/Aβ, GM2 ganglioside, and endosomal-pH surrogates as pharmacodynamic readouts.
  4. Genotype-stratified therapeutic matching — test chaperone/trafficking correction for ER-retained missense variants (e.g., ΔWST) vs gene replacement for null variants, building on iPSC mutation-specific rescue data.
  5. Combination therapy testing — pair partial gene replacement with TrkB agonism (7,8-DHF) and/or autophagy enhancers (trehalose) to address both developmental and degenerative arms.
  6. In-vivo validation of the CDK5/TRPV1 scaffolding axis and its contribution to the pain phenotype and seizure susceptibility.
  7. Re-verify the gain-of-function variant citation ([PMID: 30296617]) and reconcile with the loss-of-function paradigm.

Report compiled from 41 reviewed publications and 9 confirmed findings across a 5-iteration autonomous investigation. Evidence types are labeled (human clinical, model organism, in vitro) throughout. Ontology term suggestions (HPO, GO, CL, UBERON, NCIT) are provided in the relevant sections for knowledge-base ingestion.

Artifacts

Citations

  1. PMID:37987014
  2. PMID:25044251
  3. PMID:24035762
  4. PMID:39341363
  5. PMID:21964919
  6. PMID:36055242
  7. PMID:34928329
  8. PMID:40722028
  9. PMID:32569089
  10. PMID:41934608
  11. PMID:39868272
  12. PMID:31175985
  13. PMID:27256868
  14. PMID:24630051
  15. PMID:29772390
  16. PMID:30296617
  17. PMID:29946028
  18. PMID:41933339
  19. PMID:24090639
  20. PMID:42051037
  21. PMID:24285247
  22. PMID:39237363
  23. PMID:32737755
  24. PMID:34791706
  25. PMID:31676550
  26. PMID:29567836
  27. PMID:37747131
  28. PMID:22541666
  29. PMID:26515654
  30. PMID:37213903
  31. PMID:20949524
  32. PMID:31879735
  33. PMID:33568516